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ABSTRACT
Group 1 and 2 house dust mites (HDM) allergens elicit IgE response in more than
80% of sensitized individuals. These allergens affect 10-30% of the world’s population.
Prolonged inhalation of low doses of allergens (microgram amounts inhaled over months
or years) by genetically predisposed individuals leads to the induction of a Th2-type
immune response induced by allergen-specific immunoglobulin E (IgE) produced by
plasma cells resulting in allergic diseases like asthma, atopic dermatitis, and rhinitis. Group
1 and 2 HDM allergens, in particular, are associated with the development of the
aforementioned allergic diseases. The goal of this research was to characterize properties
of Group 1 and 2 HDM allergens related to their structure, function, and interactions with
monoclonal antibodies (mAbs). Structural studies, specifically X-ray crystallography, were
used to identify important residues responsible for antigen-antibody interactions. Protein
characterization and analysis of the antigenic surface of these allergens enabled the design
of allergen mutants with defined three-dimensional structure, reduced IgE reactivity, and
retained T cell epitopes for production of hypoallergens to be utilized in HDM allergy
immunotherapy.
Another family of allergens studied in this research were profilins. This family
shares high amino acid sequence identities and similarities even between distantly related
members. This sequence homology can lead to IgE cross-reactivity resulting in pollen-food
syndrome. Details on protein production, thermal stability, and allergen sensitization
studies in patients with pollen-food syndrome are presented herein. Understanding the
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immunological, molecular, and structural properties of profilins will demystify the clinical
importance of profilins in pollen-food syndrome.
Lastly, in this research, a new robust way of predicting IgE cross-reactivity between
two allergens belonging to the same protein family was developed. The A-RISC index
(Allergens’–Relative Identity, Similarity and Cross-reactivity) results in a single numerical
value which enables the likelihood of IgE cross-reactivity to be grouped into four
categories: high, medium-high, medium-low and low. The proposed approach can facilitate
analysis in component-resolved allergy diagnostics, generate avoidance guidelines for
allergic individuals, and assist with the design of immunotherapy. This research will
facilitate future immunotherapy, vaccine design and component-resolved allergy
diagnostics in not only profilins and HDM allergies, but in all other relevant types of
allergies.
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INTRODUCTION TO ALLERGENS
Nearly 50 million Americans suffer from allergies, constituting them as the sixth
leading cause of chronic illnesses in America [1]. Worldwide, about 30-40% of the world’s
population suffer from one, or more allergic conditions [2]. Allergies are a hypersensitivity
to normally harmless substances. When this happens, these harmless substances are
denoted as allergens. Exposure to low doses of allergens over time primes a patient’s Th2type immune response with allergen-specific immunoglobulin E (IgE) production by
plasma cells, which then leads to allergic diseases [2]. There are many types of allergens
present in the world, emanating from a plethora of sources. The sources include, but are
not limited to, drugs, food, pollen and dust; they can be inhaled, ingested, injected, and/or
contacted [3]. To make it easier for both researchers and clinicians to navigate through the
“jungle of allergens”, more than three decades ago, formal allergen nomenclature was
created. Allergen names are composed of an abbreviation of the scientific name of its
source (genus: 3–4 letters; species: 1–2 letters) and an Arabic numeral. For example, an
allergen from chicken, Gallus domesticus, is named Gal d 1 [4].
Currently, there are over one thousand allergens identified and registered with the
World Health Organization and International Union of Immunological Societies
(WHO/IUIS) Allergen Nomenclature Sub-committee. These allergens are distributed
between 151 families [3]. Interestingly, allergens arise from relatively few protein families
which represent only a small fraction of the protein families described in the Pfam database
[3,5,6]. To differentiate between allergens and non-allergens, the IUIS demarcates a protein
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to be an allergen if it induces an IgE-mediated (atopic) immune response in humans with a
prevalence of IgE reactivity above 5%. However, although it does not carry any
connotation of allergenic potency, an allergen is termed as being major if it is recognized
by IgE in at least 50% of a cohort of allergic individuals sensitized to a given allergenic
source; it is otherwise known as minor [7]. Please note that proteins are not the only
molecules that can be an allergen. However, other types of allergens (antibiotics, metals,
etc.) were not studied in the research.
Interactions between IgE and allergens are crucial for allergic diseases, as the
formation of an allergen-antibody complex is necessary for triggering an allergic reaction.
The IgE-mediated allergic reaction requires an allergen to cross-link the IgE antibodies
bound to the high-affinity receptors located on mast cells [8]. This cross-linking triggers a
cascade of events leading to the degranulation of mast cells releasing proinflammatory
mediators such as histamine. This results in allergic reaction symptoms in the skin, gastrointestinal tract, and respiratory system. These can include oral itching, lip swelling, labial
edema, and even deadly reactions such as anaphylactic shock [8]. Retrospectively,
understanding the chemical and physical interactions that occur between an allergen and
an antibody is an indispensable tool in allergy diagnostics and therapeutics.
Studying the allergen-antibody binding interface which comprises of the antigen
binding site, epitope, and the antibody binding site, paratope, immensely contribute to
understanding the molecular basis of allergy and allergic diseases. However, studying
allergen-antibody interactions is further complicated by IgE cross-reactivity between
different allergens. Cross-reactivity occurs when the antibodies raised against one allergen,
cannot distinguish between that allergen and a structurally similar protein, and thus, bind
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to the secondary protein [9]. Because IgE binding epitopes are conformational, they can
experience substantial cross-reactivity with proteins of high sequence identity, especially
on surface residues [10]. In nature, some allergens exist as isoallergens— allergens from a
single species sharing similar molecular size, identical biological function and >67% amino
acid sequence identity [7]. Additionally, the same allergen can be represented by several
variants called isoforms. These isoforms typically have high sequence identity of more than
97%. Due to high sequence homologies and three-dimensional structures, isoallergens and
isoforms share extensive antigenic cross-reactivity [7].
Although allergen extracts derived from natural sources are currently the main
source of allergens used for allergy diagnosis and treatment, they contain other antigens
and antigenic proteins which presumably might interfere with allergy treatment [11].
Additionally, the relative and absolute concentration of specific isoforms in individual
extracts may differ. This is especially problematic as it has been shown that one isoform
may be more antigenic than others, and that monoclonal antibodies raised against some
potent allergens can sometimes discriminate between different isoforms [12,13].
Contrarily, recombinant allergens can provide not only standardized and known doses of
allergens, [14] but, can also be easily modified to provide hypoallergenic variants having
reduced IgE reactivity that may then be used in immunotherapy [11].
It is hypothesized that characterization of molecular and antigenic properties of
allergens is necessary for the development of better allergy diagnostics and therapeutics.
The main mandate of this research was to study the structural, functional and
immunological characteristics of HDM and profilin allergens for allergen specific
diagnostics and immunotherapy (Figure 1.1). Protein characterization and analysis of the
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antigenic surface of these allergens in contact with antibodies will facilitate allergy
diagnostics and enable the design of hypo-allergens, with reduced IgE reactivity and
retained T cell epitopes, for production of allergy vaccines and immunotherapy.
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CHAPTER 1
STRUCTURAL, FUNCTIONAL AND IMMUNOLOGICAL STUDIES OF
GROUP 1 AND 2 HOUSE DUST MITE ALLERGENS FOR EPITOPE
RESOLVED ALLERGY DIAGNOSTICS AND IMMUNOTHERAPY1,2

1.1 BACKGROUND AND INTRODUCTION TO HOUSE DUST MITE
ALLERGENS
Dust mites are arthropods that thrive in warm areas of high humidity and feed on
human skin flakes. In many households, dust mites are found almost everywhere including
beds, carpets, and other furniture. Inhalation of HDM allergens, excreted in the mites’ fecal
matter, is one of the most significant risk factors which leads to allergic diseases such as
asthma, atopic dermatitis and rhinitis [15]. More than 22 million people in the USA alone
who are exposed and sensitized to dust mites have developed asthma, a chronic
inflammatory disease of the airways [16,17].
__________________________________
1

Glesner J., Kapingidza A. B., Godzwon, M., Offermann L. R., Mueller, G. A., DeRose
E. F., Wünschmann S., London R. E., Chapmann M. D., Ohlin M., Chruszcz M. and Pomés
A. (2019). The Journal of Immunology 203 (9): 2545-255
Reprinted here with permission of publisher.
2

Kapingidza A. B., Hyduke N., Glesner J., Dolamore C., Easley W., Schlachter C., Pomés
A. and Chruszcz M.
To be submitted to Molecular Immunology.
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Up to 85% of asthmatics are sensitized to house dust mites, and this number may
exceed 90% in the tropics [18]. Globally, dust mite allergies occur in about 10-30% of the
population [19]. In HDM allergy, IgE mediated immune response is elicited from two
major dust mite species, Dermatophagoides farinae and Dermatophagoides pteronyssinus.
These species are both sources of potent major allergens that stimulate IgE mediated
immune response in more than 85% of sensitized individuals [20]. Although more than 35
groups of dust mite allergens (Table 1.1) have been identified, Group 1 and 2 allergens
have been found to be among the most important sources of potent allergens [20]. Studies
have shown that Group 1 and 2 mite allergens combined bind 50–70% of the IgE that
recognizes mite extracts [18]. Group 1 dust mite allergens (Der f 1 and Der p 1) are cysteine
proteases whereas Group 2 (Der f 2 and Der p 2) belong to the Niemann Pick C2 (NPC2)
family, which are proteins of approximately 130 amino acids that form a single β-sandwich
domain [21].
Group 1 mite allergens, Der f 1 and Der p 1, have 81% sequence identity while
Group 2 allergens, Der f 2 and Der p 2, have 88% identical amino acids (Figure 1.2). Due
to this high sequence homology both Group 1 and 2 HDM allergens homologues exhibit
significant IgE cross-reactivity. For example, Der p 2 was shown to have high risk of crossreactivity with its D. farinae homologue, Der f 2, and Eur m 2 (Euroglyphus maynei,
originating from a European HDM and shares 83% sequence identity with Der p 2) [9].
Both Group 1 and 2 HDM allergens independently elicit IgE production in more than 80%
of HDM allergic patients. Due to this high sensitization rate, the two groups are classified
as major allergens [20].
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The allergenicity preeminence of Group 1 and 2 HDM allergens is attributed to the
intricate mechanism these two groups of allergens interact with the human immune system.
In retrospect, the proteolytic activity of Group 1 mite allergens has been proven to
contribute to their allergenicity [22]. Group 1 mite allergens cleave CD23 and CD25
receptors on mast cells, B-cells, T-cells and other immune cells involved in allergy immune
response [21,23]. Cleavage of these receptors activates a cascade of events that lead to the
release of proinflammatory cytokines by many immune cells including mast cells and
basophils leading to a Th2 immune response. This results in the increase in IgE antibody
production and inflammation of lung epithelium [24]. This helps explain why dust mite
sensitization in very high among asthma patients. On the other hand, however, Group 2
dust mite allergens show structural homology to and are mimickers of Lymphocyte antigen
96, also known as MD-2, a lipopolysaccharide binding protein associated with Toll-like
Receptor 4 (TLR-4) of the Toll-like receptor pathway. Due to this mimicry, Group 2 mite
allergens can activate the innate immune system through TLR-4 resulting in a 95%
prevalence of IgE antibodies response among asthmatics [25].
The only available treatment for mite allergies consists of administering increasing
doses of mite allergen extracts, which can cause adverse reactions to the patient (release of
mediators such as histamine and inflammation) [26]. The primary objective of this research
project was to produce hypo-allergenic molecules that have reduced reactivity to human
IgE antibody for the development of better immunotherapy for HDM allergic patients.
These hypo-allergens will decrease the adverse reactions presently observed in
conventional immunotherapy.
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We hypothesized that molecular, structural, and immunological characterization
of allergens in complex with antibodies is indispensable to the future of allergy diagnostics
and immunotherapy. To test this hypothesis, we studied Group 1 and 2 HDM allergens
and their interactions with murine–derived IgG and/or human-derived IgE antibodies. The
murine-derived antibodies used were known to interfere with IgE binding, hence their
epitopes overlap [26]. In this case, IgG was used to study IgE binding because of its higher
concentration in blood sera than IgE and increased propensity to crystallize [27].
The research was carried out in three steps: 1) Expression, purification and
characterization of recombinant allergens and IgE/IgG antibody fragments (the IgG were
from mouse hybridomas and the IgE constructs were selected from combinational libraries
designed from HDM allergic patients), 2) Identification of IgE/IgG epitopes on Group 1
and 2 allergens by generating allergen-antibody complexes, and 3) Design and production
of Group 1 and 2 HDM allergen mutants with reduced IgE binding affinity (Figure 1.3).
Since most IgE epitopes are conformational, X-ray crystallography provides detailed threedimensional structural features of the IgE antibodies in complex with allergens, unveiling
the important residues responsible for allergen-antibody interactions. Our previous
research on Group 1 HDM allergens have proven that only a small number of residues
within an epitope are functionally important for IgE antibody binding [28-30]. Hence, after
the identification of these “hot-spots,” using site-directed mutagenesis, two double mutants
on the 7A1epitope were generated. IgE binding affinities between the wild type natural
and/or recombinant allergens and the mutants were compared using ELISA (enzymelinked immunosorbent assay). These allergen mutants with reduced IgE binding are good
candidates in the development of HDM vaccines and immunotherapy.
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1.2 EXPRESSION AND PURIFICATION OF RECOMBINANT GROUP 1 AND 2
HDM ALLERGENS
Over the years, several attempts were made to express Group 1 mite allergens in
Escherichia coli (E. coli) or any other prokaryotic system without any success [31,32].
Hence, since Group 1 dust mite allergens, Der p 1 and Der f 1, require eukaryotic
expression systems [33] these allergens were provided by our collaborators, Dr. Anna
Pomés and her group at Indoor Biotechnologies (Charlottesville, VA). Two isoforms of
Group 2 dust mite allergens Der p 2.0101 and Der p 2.0103 were cloned and expressed in
E. coli and purified by Immobilized Metal Affinity Chromatography (IMAC) using NiNTA (Nickel Nitrilotriacetic acid) and Size Exclusion Chromatography (SEC). Although
Der p 2.0101 and Der p 2.0103 share 98% sequence identity (Figure 1.4A), producing
different isoforms of Der p 2 was crucial because monoclonal antibodies raised against
these Group 2 HDM allergens can sometimes discriminate between different isoforms
[13,12].
Gene coding for Der p 2.0101 and additional N-terminal purification tag was
synthesized and inserted into pJExpress411 plasmid (Kanamycin resistance) by DNA 2.0
(currently ATUM, Newark, CA). The Der p 2.0101 insert was designed with a cleavable
N-terminal cleavable purification His-tag MHHHHHHSSGVDLGTENLYFQ!SGSG,
where the exclamation mark denotes the Tobacco Etch Virus (TEV) protease cleavage site.
The plasmids were transformed into E. coli BL-21 (DE3) cells. One-liter Lysogeny Broth
(LB) cultures were grown to an OD600 of 0.8 and induced with 500 µM isopropyl β-D-1thiogalactopyranoside (IPTG), cooled to 16°C, and grown overnight. Cell pellets were
resuspended in lysis buffer (20 mM Tris-HCl, 500 mM NaCl, 2% glycerol, 10 mM
imidazole, pH 7.4) and lysed by sonication. The sonicated mixture was centrifuged at
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9,000xg and a cell pellet was obtained. The supernatant was loaded onto a Bio-Rad EconoPac chromatography column equilibrated with (50 mM Tris, 500 mM NaCl, 30 mM
imidazole, 2% glycerol, pH 7.4) containing HisPur Ni-NTA resin. The protein was eluted
using elution buffer (50 mM Tris-HCl, 50 mM NaCl, 250 mM imidazole, 2% glycerol, pH
7.4).
Elutions containing protein were determined by Sodium Dodecyl SulphatePolyacrylamide Gel Electrophoresis (SDS-PAGE), then pooled and dialyzed overnight by
using Pierce SnakeSkin Dialysis Tubing and dialysis buffer (50 mM Tris-HCl, 150 mM
NaCl, pH 7.4). The dialyzed protein was concentrated using a Millipore Amicon Ultra
concentrator with a 3,000 Da molecular mass cutoff and was further purified by SEC using
a GE Healthcare ÄKTA-Pure FPLC and HiLoad Superdex 200 column. Fractions
containing protein were concentrated as before and Der p 2.0101 concentration was
determined by using a Thermo Scientific™ NanoDrop 2000 and purity by SDS-PAGE
(Figure 1.4B). The protein was unstable and most of it precipitated or formed aggregates
on the SEC column. The yield was 2.5 mg/L of culture.
Attempts to cleave the N-terminal His-tag with TEV protease resulted in loss of
significant amounts of protein. Therefore, a new construct without the purification tag was
designed. The knockout construct did not express well in E. coli BL-21 (DE3). The
instability of the Der p 2.0101 isoform both with and without the His-tag was thought to
be caused by the misfolding of the protein. Der p 2 forms three disulfide bonds in its natural
state which are important for its function [20]. The importance of these three disulfide
bonds for protein folding and stability was confirmed previously [34]. Mutants of
recombinant Der p 2 lacking each of the three disulfide bonds were generated. The variant
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lacking the C21-C27 disulfide bond showed up to a 40-fold reduction in antibody binding
and the mutant lacking C73-C78 disulfide bond showed more than a 100-fold reduction in
IgE binding and failed to bind four antibodies [34]. Hence, these disulfide bonds play a
crucial role in stabilizing the antigenic structure of Der p 2 and their presence in
recombinant Der p 2 is required for proper folding. Therefore, it was reasoned that it was
better to express the protein in a cell line that favors disulfide bond formation. Thus, the
protein was expressed in E. coli T-7 Shuffle cells [35] using the same expression conditions
mentioned above.
The Der p 2.0101 protein without His-tag was purified by ion exchange
chromatography using DEAE (diethylaminoethyl) column connected on ÄKTA Pure
FPLC system (GE Healthcare). To remove excess salt from the ion exchange
chromatography, the protein was dialyzed overnight in 50 mM Tris and 150 mM NaCl, pH
7.4. The protein was then purified by SEC, but all of it precipitated on the column. Despite
attempts to increase the protein yield and stability, the Der p 2.0101 isoform was unstable
and degraded at 4°C in just one week. A later section will discuss how the instability of the
Der p 2.0101 isoform was solved.
For the Der p 2.0103 isoform, cloning, expression and purification conditions were
changed substantially from those used for Der p 2.0101. DNA encoding for Der p 2.0103
isoform was synthesized with an N-terminal cleavable His-tag just like the Der p 2.0101
isoform and inserted into a kanamycin-resistant pET26b (+) plasmid by Bio Basic
(Amherst, NY). The Der p 2.0103 gene was cloned in frame with a pelB leader sequence,
a sequence of amino acids which when attached to a protein, directs the protein to the
periplasmic membrane of E. coli for expression of proteins in the periplasm [36]. The
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plasmid was co-transformed into E. coli BL-21 (DE3) strain together with protein disulfide
isomerase 1, or PDI-1, plasmid (ampicillin resistance). PDI-1 is an enzyme located in the
periplasm of bacteria and eukaryotes that catalyzes the breakage and formation of disulfide
bonds between cysteine residues found within proteins as they fold [37]. Hence, PDI was
used to aid disulfide bond formation in recombinant Der p 2 isoforms during expression in
E. coli.
One-liter terrific broth (TB) cultures were grown at 37°C to OD600 of 0.4 shaking
at 200 rpm. The cultures were cooled to 22°C or room temperature, and grown to an OD600
of 0.8-1.0 and then induced with 500 µM of IPTG, cooled to 16°C, and grown for 16–18
hrs. Cell pellets obtained after centrifuging the overnight one-liter cultures were
resuspended in lysis buffer (20 mM Na2HPO4, 500 mM NaCl, and 10 mM imidazole, pH
7.4). After sonication, the cell lysate was centrifuged at 9000xg for 10 min at 4°C. The
supernatant was purified by immobilized metal affinity using Ni-NTA. After loading the
protein onto the column, the column was washed with wash buffer (20 mM Na2HPO4, 500
mM NaCl, and 30 mM imidazole, pH 7.4). The protein was collected using elution buffer
(20 mM Na2HPO4, 500 mM NaCl, and 300 mM imidazole and pH 7.4). The protein was
further purified by SEC (Figure 1.5) in elution buffer. Protein purity was confirmed by
SDS-PAGE. The final yield of the Der p 2.0103 isoform was 7 mg/L of culture. The
obtained protein was used to set crystallization plates with Der p 2 specific antibodies.
1.3 GENERATION, EXPRESSION AND PURIFICATION OF ALLERGEN
SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS
To identify antibody binding epitopes for Group 1 and 2 dust mite allergens,
allergen-antibody complexes were made. Using hybridoma technology our collaborators
at Indoor Biotechnologies generated Group 1 and 2 HDM specific murine monoclonal
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antibodies that had been isolated by Dr. Martin D. Chapman at the University of Virginia.
Dr. Mats Ohlin, a collaborator in the NIH/NIAID R01 grant at Lund University, isolated
IgE constructs from HDM allergic subjects using phage display technology which was later
used by Dr. Anna Pomés’ group [26,29]. Hence, in this research, Dr. Anna Pomés and her
group at Indoor Biotechnologies, provided us with whole IgE and IgG antibodies, as well
as amino acid sequences encoding for the antibody variable domains specific for both
Group 1 and 2 HDM allergens (Figure 1.3). Although whole IgE antibodies are the best
candidates to be used in studying the interactions between Group 1 and 2 dust mite
allergens and the human immune system, the amount of IgE antibodies that can be
extracted from sera is very low [38,39]. Therefore, the ability to produce recombinant IgE
and IgG antibody fragments like single-chain variable fragments (scFvs) and antibody
fragments (Fabs) (Figures 1.6 and 1.7) selected from combinational libraries designed from
HDM allergic patients (and sometimes mice) makes it possible to acquire significant
amounts of recombinant allergen specific IgE and IgG antibodies suitable for use in X-ray
crystallography and various other assays [26,28,40].
The important part of an antibody are the variable regions which contain the antigen
binding sites, called complementary determining regions (CDRs), (Figure 1.6) and because
antibody fragments also possess these regions (Figure 1.7), they still have the same antigen
specificity as full-length antibodies [27]. Antibody fragments also have other advantages
over full length antibodies such as their ease of manufacturing and manipulating compared
to full antibodies that are at least 150kDa [41]. Full antibodies are also too flexible for
crystallization of allergen-antibody complexes for X-ray crystallography experiments. As
mentioned above, Dr. Anna Pomés and her group at Indoor Biotechnologies provided the
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whole IgE and IgG antibodies and often-times allergen-antibody complexes, for
crystallization purposes, were made using intact full antibody. Although no one can predict
the results of a crystallization experiment [42], it is an established fact that the flexibility
of full antibodies considerably reduces the probability of a crystal forming [43]. To combat
the flexibility, papain (or sometimes ficin) was used to cleave the crystallizable fragment
(Fc) regions of IgG-derived antibodies to produce Fabs for use in crystallization
experiments and other assays.
1.4 PAPAIN PROTEOLYTIC CLEAVAGE OF FC REGIONS AND
PURIFICATION OF IGG MONOCLONAL ANTIBODIES
Papain proteolytic cleavage of whole IgG antibodies was used to obtain antibody
fragments. Fabs of Group 1 and 2 specific IgG antibodies were cleaved and purified using
the Pierce Fab preparation kit from Thermo Fisher as per the manufacturer’s protocol.
Following cleavage of the whole antibody and purification of the Fab fragments, all
experiments were conducted using just the Fab fragments.
To prepare the allergen-antibody complexes, the allergen was mixed with the IgG
Fab fragment in a 1:1 molar ratio and incubated at 4°C from one hour to overnight. After
incubation, the solution was concentrated using an Amicon Ultra concentrator (Millipore)
with a 10,000 Da molecular mass cutoff and purified by SEC on a Superdex 200 column
attached to an ÄKTA Pure FPLC system (GE Healthcare). A 20 mM Na2HPO4, 500 mM
NaCl, 250 mM imidazole, and pH 7.4 buffer was used for SEC. (SEC was only conducted
to test to see binding of allergen to antibody, but it was not always carried out). After SEC,
fractions containing the Allergen-Fab complex were concentrated as mentioned above. The
allergen-antibody complexes were then used for crystallization experiments.

14

1.5 EXPRESSION AND PURIFICATION OF GROUP 1 HDM SPECIFIC
ANTIBODY FRAGMENTS
In this research, several full antibodies and antibody fragments specific to Group 1
mite allergens were generated. Before the work presented in this manuscript was
conducted, the Chruszcz’ lab had extensively characterized the structure of antigenic
determinants of Group 1 HDM allergens in complex with antibodies and Dr. Pomés’ lab
performed the mutagenesis and immunologic analysis of the epitopes [29,40,44]. However,
most of the antibodies and antibody fragments used then were mainly monoclonal
antibodies obtained from papain proteolytic cleavage of full antibodies, so there was need
to attempt to produce recombinant versions of the same antibodies. In addition, some of
the allergen specific antibodies such as the murine-derived mAb 6A8, specific to Der f 1,
was not exhaustively characterized, and the crystal structure was not yet determined.
Several antibodies in different formats specific to Group 1 HDM allergens were
studied in this research (Table 1.2), and, as mentioned before, full mAb and Group 1 mite
allergens were provided by our collaborators, Dr. Anna Pomés and her group at Indoor
Biotechnologies. Fabs for recombinant antibody 4C1 and 1C14 (anti-Der p 1 antibody)
were obtained using papain proteolytic as outlined above and the proteins were all used to
set crystallization plates in complex either with Der p 1 or alone. However, IgG murinederived mAb 6A8 and Der f 1 specific antibody was the primary antibody worked on in
this research.
1.6 DER F 1 SPECIFIC MAB 6A8 CONSTRUCTS, EXPRESSION,
PURIFICATION AND CRYSTALLIZATION
Monoclonal antibody 6A8 has been widely used for decades both in commercial
purposes and in research. This antibody binds to a species-specific epitope on Der f 1
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distinct from the epitope bound by the cross-reactive mAb 4C1 that binds both Der f 1 and
Der p 1 [45]. Despite its extensive use, the crystal structure of mAb 6A8 has not been
elucidated [30,45]. Furthermore, there is no literature that elaborates on the expression of
this important antibody recombinantly. In the quest to crystallize mAb 6A8, milligram
amounts of the antibody were needed. To meet this demand, after attaining the amino acid
sequences that encode for the mAb 6A8 heavy and light chain regions from Dr. Anna
Pomés and her group at Indoor Biotechnologies, antibody constructs in the form of scFvs
were made.
The scFv format was chosen because the size of the antibody is considerably
reduced to about 25 kDa which makes it easier for expression in E. coli and is also one of
the simplest antibody formats to work with [46]. Single chain antibody fragments are made
when the variable regions of light and heavy antibody chains encoding antigen-binding
domains are engineered into a single polypeptide with a flexible linker comprising of only
glycines and serines put in between the two regions. The glycines increase flexibility, and
serines increase solubility [46,47] (Figure 1.7). At first, the 6A8 scFv was cloned,
expressed and purified the same way as the Der p 2 isoforms mentioned above, however
both the methods used failed. SDS-PAGE results showed no expression. Several E. coli
strains including T-7 Shuffle cells and changing growth conditions yielded no amount of
detectable protein. However, a literature search revealed that some proteins can be toxic to
E. coli leading to little or no expression of such proteins. Fortunately, the C41 E. coli cell
line was developed for such proteins and was available in the lab [48].
Gene coding for 6A8 scFv and an additional non-cleavable C-terminal purification
tag (Figure 1.8) was synthesized and inserted into pET22b (+) plasmid (ampicillin
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resistance) by Bio Basic (Amherst, NY). The plasmid was transformed into E. coli C41
cells. One-liter TB cultures supplemented with kanamycin were grown to OD600 of 0.4 at
37°C and then the temperature was lowered to room temperature. The cultures were shaken
until OD600 of 1.0-1.2 then induced with 500 µM IPTG, cooled to 16°C, and grown
overnight. Cell pellets were resuspended in lysis buffer (50 mM Tris-HCl, 500 mM NaCl,
2% glycerol, 10 mM imidazole, pH 7.4) and lysed by sonication. The sonicated mixture
was centrifuged at 9, 000xg to obtain a cell pellet. The supernatant was loaded onto a BioRad Econo-Pac chromatography column equilibrated with (50 mM Tris, 500 mM NaCl, 30
mM imidazole, 2% glycerol and pH 7.4) containing HisPur Ni-NTA resin. The protein was
eluted using elution buffer (50 mM Tris-HCl, 50 mM NaCl, 250 mM imidazole, 2%
glycerol, pH 7.4). SDS-PAGE showed that expression of 6A8 scFv had been considerably
enhanced (Figure 1.9).
Elutions containing protein were determined by SDS-PAGE pooled and
concentrated using a Millipore Amicon Ultra concentrator with a 3,000 Da molecular mass
cutoff. The scFv was further purified by SEC using a GE Healthcare ÄKTA-Pure FPLC
and HiLoad Superdex 200 column. Elution buffer was used for SEC. The protein was
unstable and most of it precipitated and/or aggregated on the SEC column. The yield was
approximately 1.5mg/L of culture or less. The 6A8 scFv instability was such that the
protein would degrade at 4ºC after just 4 days. To test the binding affinity of the scFv to
natural Der f 1 (nDer f 1), this unstable protein was sent to Dr. Anna Pomés and her group
at Indoor Biotechnologies for ELISA (Enzyme-Linked Immunosorbent Assay)
experiments. Interestingly though, the protein did bind to Der f 1 (results not shown).
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It was reasoned that the instability of the scFv might have been caused by
misfolding of the protein. This was a credible rationale because research has demonstrated
that in the design of the scFv antibody construct the length of the linker plays a crucial role
in the folding of the protein. Too long of a linker could lead to over-flexibility of the scFv
resulting in misfolding and instability of the protein [49]. The first 6A8 scFv construct had
a linker comprising of 15 amino acid residues (GGGGS) 3; hence we reduced the linker
length to 10 amino acids (GGGGS)2 (Figure 1.8). Despite these changes, 6A8 scFv was
still unstable.
Although expressing mAb 6A8 in the scFv format was tested thoroughly, the results
acquired were somewhat expected because scFv antibody fragments are notoriously known
for their instability and low expression in E. coli expression systems [50]. Retrospectively,
we changed the format of the antibody to Fabs. The difference between an scFv and a Fab
is that the Fab contains constant regions and is connected by a disulfide bridge (Figure 1.7).
This can make a considerable difference in the stability and sometimes even increase the
affinity of the antibody to its antigen [51] (Figure 1.8). Gene coding for the light chain
variable and constant regions with a C-terminal non-cleavable His-tag were cloned into a
pET22b (+) plasmid with the heavy chain being cloned into a pET26b (+) plasmid by Bio
Basic (Amherst, NY). The plasmids were co-transformed into C41 cells and the same
expression and purification conditions explained above for the 6A8 scFv were used. SDSPAGE confirmed the expression of both the light and heavy chain in considerable amounts.
However, the light chain was more abundant than the heavy chain (Figure 1.10). After
SEC, the light chain had a final yield of 6-8 mg/L of culture. The protein was significantly
more stable (could survive for about 2 weeks at 4°C) than any other mAb 6A8 proteins
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made before. Crystallization plates were set using thousands of crystallization conditions.
Fortunately, the protein crystallized within a couple of weeks, but upon determination of
the crystal structure, it was found that the crystallized protein was a 6A8 light chain dimer,
not a Fab. Despite several attempts made to also over-express mAb 6A8 heavy chain and
crystallize the antibody as a Fab, only crystals of the light chain dimers were obtained
(Figure 1.11)
1.7 CRYSTALLIZATION, DATA COLLECTION AND STRUCTURE
DETERMINATION OF 6A8 LIGHT CHAIN DIMER
Crystallization of the 6A8 light chain dimer was performed at 277 K. The best
diffracting crystals were grown using the sitting drop vapor diffusion method. The crystals
were obtained when 5 mg/mL protein sample was mixed in a 1:1 volume ratio with well
solution composed of 0.2 M ammonium sulfate, 0.1 M Bis-Tris at pH 5.5, and 25% w/v
polyethylene glycol 3,350. Data collection for the 6A8 light chain dimer was performed
remotely using the Southeast Regional Collaborative Access Team (SER-CAT) 22-ID
beamline at the Advanced Photon Source (APS), Argonne National Laboratory (Lemont,
IL).
Data were processed with HKL-3000 [52] and structure was determined using
MOLREP [53] incorporated into HKL-3000 and molecular replacement method. PDB
structure 3RVU was used as a search model. The model was rebuilt with Buccaneer [54]
and ARP/wARP [55]. Model refinement was performed using REFMAC [56] and HKL3000. Some programs from the CCP4 package [57] were used for data handling. The model
was manually adjusted using COOT [58]. COOT and MOLPROBITY [59] were used for
model validation. TLSMD [60] was used for determination of TLS groups used during
refinement.
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1.8 MAB 6A8 LIGHT CHAIN DIMER STRUCTURE ANALYSIS
The 6A8 light chain dimer X-ray crystal structure was determined in the C222 space
group at 2.80 Å resolution with one dimer in the asymmetric unit (Table 1.3). One chain is
comprised of two β-sandwich motifs as is common of most of light chain dimers in the
PDB [61] (Figure 1.12). The β-sandwich of the constant region is comprised of seven
antiparallel β-strands bounded by α-helices on the side opposite the variable region. The βsandwich of the variable region is comprised of ten antiparallel β-strands bounded by one
α-helix on the same side as the constant region (Figure 1.11). The three CDRs, as predicted
by the Paratome server [62], protrude from the β-sandwich allowing for binding of the
antigen (Figures 1.11 and 1.13A). As is common with most antibodies, the 6A8 light chain
dimer contains two disulfide bonds, one between C 24 and C88 in the variable region and the
other between C135 and C195. Both disulfide bonds are buried in the middle of their
respective β-sandwich.
B-factors, also called displacement parameters, can be used to describe the relative
mobility of various atoms in the crystal structure. Atoms with higher B-factors values are
located in fragments of molecules that display a higher mobility/disorder. Figure 1.13B
shows the distribution of B-factors for the 6A8 light chain dimer. Overall, the variable
regions have lower B-factors compared to the constant regions. Constant regions have the
highest mobility/displacement of residues as denoted by the red color and the larger
diameter of ribbons. Such distribution of B-factor values can be explained by the fact that
the constant domains form less crystal contacts and are more exposed to the solvent.
Contrarily, the variable domains are involved in more interactions with neighboring
molecules, which is leading to the restriction of their movement within the crystal lattice.
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This is represented by lower B-factor values (shown by the blue color and the smallest
ribbon diameter; Figure 1.13B).
There are two interfaces that are responsible for the light chain dimer formation.
One of the interfaces is formed by the constant regions and the other by the variable
regions. PDBePISA [63] analysis indicates the interface between the two chains is
comprised of approximately 44 residues from each chain covering an area of about
1,200Å2. The dimer is stabilized by various hydrophobic interactions, as well as hydrogen
bonding (Table 1.5). The following residues, however, contribute the most area to the
interactions on the dimer interface: N35, L37, Q39, I45, R47, D56, Y88, L90, P96, W97, F99, G100,
F119, V134, F136, S163 and T165. Despite the structure being a homodimer, the chain
conformation is not identical. For example, Asp168 and Ser177 from chain B contribute
towards hydrophobic interactions in the interface, but both these residues from chain A do
not contribute to the interface interactions.
1.9 OTHER ANTIBODY FRAGMENT CONSTRUCTS MADE FOR MAB 6A8
In the quest to obtain a Fab for mAb 6A8, other constructs were made. (All the
expression plasmids used hereafter were also cloned by Bio Basic (Amherst, NY). The
same expression and purification methods used for the scFv were employed for all the other
mAb 6A8 antibody formats). To start with, we employed a multi-gene expression system,
the pETDuet-1 plasmid, that enables expression of two proteins using one plasmid [64].
By using this system, it was reasoned that both the heavy and light chain would be
expressed in equimolar amounts. The heavy chain and light chain were expected to make
a complex in vivo, therefore the C-terminal histag was eliminated from the light chain
(Figure 1.8). Interestingly though, the heavy chain was now more abundant than the light
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chain, and the light chain neither bound to the heavy chain in vivo nor was obtained in flow
through during Ni-NTA. However, the heavy chain was unstable and precipitated on the
SEC column. Attempts were made to complex the heavy chain and the light chain (obtained
from the light chain expressed alone), but the heavy chain still precipitated on the SEC
column to obtain just the light chain.
Finally, drastic measures were implemented to coerce the two antibody chains to
make a complex, so fusion proteins with glutathione S-transferase (GST) were made. GST
is commonly used as a fusion protein to increase the stability and solubility of the protein
it is fused to [65]. However, GST also possesses another quality found in its propensity to
form dimers (Figure 1.8) [66]. At first, the heavy and light chain GST-fusion proteins were
co-expressed in C41 cells but co-expression of the two chains resulted in over-expression
of the heavy chain GST-fusion protein. This too was unstable and precipitated on the SEC
column. Afterwards, the two fusion proteins were expressed in C41 E. coli cells
individually. Because the light chain GST-fusion protein lacked the C-terminal His-tag, the
protein was purified using GST column following protocols described previously [65]. The
SDS-PAGE run after purification showed low expression of the light chain GST-fusion
protein compared to the heavy chain. The two proteins were mixed together and run on
SEC column. They both precipitated on the column and no complex was observed. Since,
all attempts employed to obtain mAb 6A8 in a stable Fab format were unsuccessful, all
experiments done thereafter were performed using the light chain dimer. In hindsight, it is
important to note that the instability of the GST-fusion proteins might have been attributed
to the fact that constant domains were omitted from the constructs.
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1.10 ELISA EXPERIMENTS: SPECIFICITY AND BINDING AFFINITIES OF
MAB 6A8 LIGHT CHAIN DIMER
After an arduous three years of trying to obtain a Fab for mAb 6A8, a thorough
review of literature reinvigorated the idea that light chain dimers were not as peculiar in
human health and surprisingly, in allergy [67]. Research showed that in the human body,
light chains are usually more abundant than heavy chains and the formation of light chain
dimers is associated with several auto-immune diseases including rhinitis [68,69]. Hence,
further experiments to investigate the binding affinity and specificity of mAb 6A8 light
chain dimer were warranted. ELISA experiments were carried out by our collaborators, Dr.
Anna Pomés and her group at Indoor Biotechnologies, to check the binding of mAb 6A8
light chain dimer (produced in this research) to Der f 1 and other allergens that exhibit high
cross-reactivity to Der f 1. Indeed, as expected, the light chain dimer could bind to Der f 1.
Conversely though, full mAb 6A8 is known to be specific to Der f 1, but the light chain
dimer did not only bind to Der p 1, but also to Der p 2.0103. To confirm and reiterate the
same results that Dr. Anna Pomés and her group had acquired, 6A8 light chain dimer was
mixed in the ratio 1:1 with Der p 2.0103 and incubated overnight at 4°C. To check the
formation of a 6A8 light chain dimer-Der p 2.0103 complex, the sample was purified by
SEC in this buffer (50 mM Tris-HCl, 50 mM NaCl, 250 mM imidazole, 2% glycerol, pH
7.4). Although not all the Der p 2.0103 bound to the 6A8 light chain dimer, some amount
of the Group 2 allergen was bound as confirmed by SDS-PAGE. This shows that the
affinity of the dimer to Der p 2.0103 is lower than the nanomolar range expected for an
antibody (Figure 1.14).
The binding of 6A8 light chain dimer to Der p 2, although a surprising result,
suggested that the protein seemed to bind allergens non-specifically, which could explain
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the difficulty we were having of co-crystallizing the dimer with an allergen. To test 6A8
light chain dimer specificity to HDM allergens, our collaborators, Dr. Anna Pomés and her
group at Indoor Biotechnologies, performed further ELISA experiments with allergens
from various sources including cat, peanuts, cockroach, and gamma globulin (Figure 1.15).
These results irrefutably confirmed that 6A8 light chain dimer will bind to almost anything,
not just the mite allergens, and it is non-specific.
1.11 PRODUCTION, EXPRESSION AND PURIFICATION OF GROUP 2 HDM
SPECIFIC ANTIBODY FRAGMENTS
As mentioned before, using hybridoma technology our collaborators at Indoor
Biotechnologies generated Group 2 HDM specific murine monoclonal antibodies that had
been isolated by Dr. Martin D. Chapman at the University of Virginia. Hence, Dr. Anna
Pomés and her group provided us with full IgG antibodies as well as amino acid sequences
encoding for the antibody variable domains specific for Group 2 HDM allergens. Three
murine-derived IgG monoclonal antibodies specific to Der p 2 were generated in this
research namely 7A1, 1D8 and αDPX. Despite many attempts done (including changing
antibody formats to Fabs) to express and purify mAb 1D8 and αDPX, the antibodies
expressed poorly and were unstable. Although many crystallization plates were set up, no
diffracting quality crystals were obtained for αDPX. It’s only recently after more than 1.5
years when one 1D8 scFv crystal diffracted, albeit poorly. Hence, no further experiments
could be carried out with the two antibodies. Conversely, one of the three antibodies, mAb
7A1, although difficult to express and purify at first, gave good results and was extensively
studied in this research.
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1.12 PRODUCTION, CRYSTALLIZATION AND STRUCTURE
DETERMINATION OF MAB 7A1 FAB
Full IgG mAb 7A1 was received from Dr. Anna Pomés and her group at Indoor
Biotechnologies, and Fabs were generated by papain proteolytic cleavage of the Fc regions
as described above. The resulting Fab were purified using a Pierce Fab Preparation Kit
(Thermo Fisher Scientific, Grand Island, NY) according to the manufacturer’s protocol.
Allergen-antibody complex was prepared by mixing the Fab fragment in a 1:1 molar ratio
with Der p 2.0103 and incubating at 4°C for 30 min. After incubation, the complex was
concentrated, purified by SEC on a Superdex 200 column using 10 mM Tris-HCl, 150 mM
NaCl, and pH 7.4 buffer. Fractions eluted from the SEC column containing Der p 2.0103
in complex with Fab from mAb 7A1 (Der p 2.0103–7A1 Fab) were pooled, concentrated
to 5 mg/mL, and used for crystallization.
Crystallization of the Der p 2.0103–7A1 Fab was performed at 298 K using the
sitting drop vapor diffusion method. The protein complex was mixed at a 1:1 ratio with
each crystallization condition. Crystallization conditions that yielded crystals of diffraction
quality contained 100 mM Bis-Tris, 200 mM ammonium acetate, and 30–55% 2-methyl2,4-pentanediol (pH 6.5) (well solution). Der p 2.0103-7A1Fab crystals were cryoprotected using well solution, then immediately cooled in liquid nitrogen. Data was
collected at the Southeast Regional Collaborative Access Team 22-ID at the Photon
Advanced Source, Argonne National Laboratory (Lemont, IL). Diffraction images were
processed using HKL-3000 [52]. Summary for data collection statistics is presented in
Table 1.4. The structure was determined using molecular replacement with PDB structures
1KTJ (Der p 2) and 3RVT (Fab) as starting models. The interpretation of the electron
density map was facilitated by the knowledge of the sequence of the variable regions of
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the antibody described above. HKL-3000, MOLREP [53], and selected programs from the
CCP4 package [57] were used for structure determination. The model was rebuilt using
Buccaneer [54] and COOT [58], refined using REFMAC [56] and COOT, and validated
using MOLPROBITY [59]. The final model together with structure factors were deposited
to the PDB with accession code 6OY4.
1.13 CRYSTAL STRUCTURE OF DER P 2.0103–7A1 FAB COMPLEX
The structure of Der p 2.0103–7A1Fab was determined at 2.45Å resolution (Table
1.4). The complex crystallized in the C2 space group with one complex copy per
asymmetric unit. The epitope has an area of ∼750 Å2, and 64% of this area corresponds to
a region that interacts with the variable fragment of the antibody heavy chain (Figure
1.16B). Most of the hydrogen-bond interactions between residues forming the epitope and
the paratope are formed by two fragments of Der p 2.0103 (Arg31-Gly32-Lys33-Pro34 and
Lys96-Ile97) that interact mostly with amino acids from CDR2 and CDR3 of the heavy chain
(H) and a residue from CDR3 from light chain (L) (L CDR3) (Figure 1.16C). Direct
contacts between allergen and antibody are not only mediated by hydrogen-bonds, but there
are several residues, such as Pro34, Pro95, Ile97, and Pro99 that participate in hydrophobic
interactions. In addition, there is a cation-pi interaction involving Lys96 (Der p 2.0103) and
Trp50 (H CDR2) with the ∼3.5 Å distance between the interacting side chains (Figure
1.16C). The structural analysis shows that Lys33 and Pro34 are responsible for a significant
fraction of the epitope area that is in contact with the L chain of mAb 7A1, whereas Lys96
and Ile97 play a similar role in the contact with the H chain. Ile97 is wedged against CDR2,
CDR1, and indirectly against CDR3, but in the last case, the interaction is mediated by a
water molecule. The epitope-paratope interactions are not only mediated by direct contacts,
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but also by indirect contacts through water molecules. In fact, the crystal structure revealed
11 water molecules (Figure 1.16B, 1.16C) that were trapped between the allergen and
antibody and participate in mediating contacts between these two molecules.
1.14 CONFORMATIONAL CHANGES UPON MAB 7A1 FAB BINDING TO
DER P 2.0103 BY X-RAY CRYSTALLOGRAPHY
In the crystal structure of the Der p 2.0103–7A1Fab, the majority of the symmetryrelated contacts are formed by the Fab fragment. Consequently, the structure provided an
opportunity to compare the conformation of the antibody bound Der p 2.0103 with the
conformation of the free allergen (Der p 2.0101; 1KTJ). The binding of mAb 7A1 Fab
induced several localized perturbations to Der p 2.0103, with notable regions including the
Glu62-Gly67 fragment (Figure 1.17A–C, small oval), along with a discontinuous sequence
of the allergen that is distal from the epitope (Figure 1.17A–C, large oval). In the former,
residues 63 and 64 showed the greatest variation, with displacement distances of 2.3Å and
3.8Å, respectively, between the two structures (Figure 1.17E; amplified view of the small
oval in Figure 1.17C). Interestingly, despite the proximity of the epitope to the
aforementioned residues, the actual epitope region experienced significantly reduced
conformational changes relative to this region (Figure 1.17F). The distal (big oval) region
encompassed a larger number of residues, potentially contributing to the increased disorder
of the region, particularly in the vicinity of the Cys 73-Cys78 disulfide bridge.
1.15 PRODUCTION, EXPRESSION AND PURIFICATION OF MAB 7A1 scFv
Although a crystal structure of mAb 7A1 in complex with Der p 2.0103 had been
obtained, more protein was needed for further experiments to characterize the
immunological and molecular characteristics of mAb 7A1. After obtaining the DNA
encoding for the heavy and light chain variable regions of mAb 7A1 from Dr. Anna Pomés
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and her group at Indoor Biotechnologies, the gene insert for the 7A1 scFv with a C-terminal
poly-histidine purification tag was cloned into the ampicillin-resistant pET21b (+) plasmid
(Bio Basic, Amherst, NY). The plasmid was co-transformed into E. coli BL-21 (DE3)
strain together with the pKJE7 (chloramphenicol resistance) plasmid that encodes for
chaperones DnaK, DnaJ, and GrpE (Takara Bio, Mountain View, CA). Plasmid cultures (1
L of Lysogeny Broth) were grown at 37°C to OD600 of 0.8, after which the cultures were
cooled to 22°C or room temperature, and were induced with 0.4 mM of IPTG, cooled to
16°C, and grown for 16–18 hrs. Cell pellets obtained after centrifuging the overnight 1 l
cultures were resuspended in lysis buffer (20 mM Na2HPO4, 500 mM NaCl, 10 mM
imidazole, and pH 7.4). After sonication, the cell lysate was centrifuged at 9000xg for 10
min at 4°C. The supernatant was purified by immobilized metal affinity using Ni-NTA.
After loading the protein onto the column, the column was washed with wash buffer (20
mM Na2HPO4, 500 mM NaCl, 30 mM imidazole, and pH 7.4). The protein was eluted
using elution buffer (20 mM Na2HPO4, 500 mM NaCl, 250 mM imidazole, and pH 7.4).
7A1 scFv protein was further purified by SEC in elution buffer. After SEC, samples
containing the protein were dialyzed in buffer containing 20 mM Na2HPO4, 150 mM NaCl,
and 100 mM EDTA at pH 7.4. The yield was 10 mg/L culture. The protein was used for
crystallization experiments and some of it was sent to our collaborators, Dr. Mueller and
his group, at the National Institute of Environmental Health Sciences (NIEHS) for
structural studies using NMR.
The purification and expression of 7A1 scFv proved difficult at first even when
various cell lines were used. Finally, BL-21 (DE3) E. coli strain along with the pKJE7
chaperone was determined to be the best for the scFv expression. In order to improve the
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protein stability and solubility, several buffer systems were tried. A comparison of Tris
and Potassium Phosphate buffers are shown in (Figure 1.18). The yield of 7A1 scFv
drastically increased from ~1 mg/L of bacterial culture to ~7-9 mg/L when sodium
phosphate buffers were used instead of Tris. The stability of the antibody was also
significantly enhanced as the protein did not degrade for 6 weeks at 4°C. 7A1 scFv would
also highly precipitate in the absence of imidazole and during freeze-thaw cycles, but the
addition of 100mM EDTA solved the problem. Although this was a great achievement, the
antibody was still considerably unstable as evidenced by the aggregates obtained during
the SEC. To troubleshoot this problem, literature review on improving the stability of
antibody fragments highlighted that co-expression of the antibody with its specific antigen
significantly increases not only the stability, but also the expression of both the allergen
and the antibody [70]. Co-expression of 7A1 scFv with Der p 2 isoforms would
simultaneously solve two problems. Please call to mind that isoform Der p 2.0101 was
also very unstable and exhibited poor expression.
1.16 CO-EXPRESSION AND PURIFICATION OF MAB 7A1 SCFV WITH
DER P 2.0101
The same expression and purification methods as mentioned above for the
production of 7A1 scFv alone were used for the expression and purification of the
7A1scFv-Der p 2.0101 complex. The SDS-PAGE after IMAC (Figure 1.19A) suggested
the allergen and antibody were expressed in 1:1 ratio. Co-expression of 7A1 scFv and Der
p 2.0101 reduced protein aggregation and increased stability, as evidenced by the SEC
chromatogram in (Figure 1.19B). After SEC, the yield of the 7A1-scFv and Der p 2.0101
complex (44.52kDa) was 10 mg/L of culture, and the single peak obtained in the elution
profile confirmed the binding of 7A1 scFv to Der p 2.0101 to form an allergen-antibody
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complex. 7A1 scFv was also co-expressed with Der p 2.0103 isoform and the same results
obtained for Der p 2.0101 were observed.
1.17 CONFORMATIONAL CHANGES BY NMR IN DER P 2 UPON
COMPLEXATION WITH MAB 7A1 SCFV
The crystal structure obtained from the 7A1 Fab-Der p 2.0103 complex suggested
that binding of mAb 7A1 significantly altered Der p 2 structure and dynamics, particularly
in the region distal from the epitope site discussed above. To further explore this
possibility, our collaborators, Dr. Mueller and his group at NIEHS, studied the complex of
mAb 7A1 scFv with Der p 2.0101 in solution using Heteronuclear Multiple Quantum
Coherence (HMQC) NMR. They generated complexes of mAb 7A1 scFv (produced in this
research) with an excess of methyl labeled Der p 2.0101. 1H-13C-NMR was used to monitor
conformational changes in 13C-methyl labeled Ile, Leu, Val side chains, a labeling scheme
which is particularly suited to maintain high sensitivity even in high molecular weight
systems [71].
Chemical shift perturbations were observed for Ile28, Leu61, Val63, and Val116, along
with a significant reduction in NMR signal intensity of Ile97 upon formation of the mAb
7A1 complex. The reduction in intensity of Ile97 are attributed to conformational exchange
upon binding. These findings were consistent with the crystal structures, in which all the
aforementioned residues that show shift changes in the NMR spectrum display
conformation changes upon mAb 7A1 Fab binding (Figure 1.17C, 1.17D). Additionally,
the slight shift in the peak for Val116 1H-13C mirrors the distal conformational changes
shown in Figure 1.17A, 1.17C, further validating the structural rearrangements observed
in the crystal structures.
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1.18 EPITOPE ANALYSIS FOR RATIONAL DESIGN OF MAB 7A1 EPITOPE
MUTANTS
The ultimate goal of this research was to design Group 2 HDM allergen mutants
with reduced IgE binding that could be exploited in HDM allergy immunotherapy. To
achieve this goal, amino acid residues critical for IgE binding had to be identified by
studying the allergen-antibody interactions on the epitope-paratope interface. The crystal
structure of the Der p 2.0103–7A1 Fab complex along with the 1H-13C-NMR studies
allowed for the identification of several allergen residues that are critical for interaction
with the antibody. Based on these insights, two double mutants (Arg31Ala-Lys33 Ala and
Lys96Glu-Ile97Glu) of the allergen were designed to decrease their ability to bind mAb 7A1.
The first set of mutations was designed to affect the interaction with the L chain
(Arg31Ala-Lys33Ala) through replacing long and positively charged side chains with
methyl groups to reduce the number of H-bonds in the epitope-paratope interface. Arg31 is
responsible for a strong interaction with Glu57 from H CDR2, whereas Lys33 participates
in formation of two hydrogen bonds with Ser95 from L CDR3 and Asp104 from CDR3 from
H chain (H CDR3). Therefore, mutation of these two residues to alanine was expected to
completely abolish their ability to form the network of H-bonds that involved their side
chains (Figure 1.16C).
The second set of mutations (Lys96Glu-Ile97Glu) targeted the interaction with the H
chain. In this study, a stretch of residues (Val94-Pro99) was identified in the structure that
lined the complex interface and might therefore play a role in antibody binding, from which
Lys96 and Ile97 were selected to be substituted (Figure 1.16C). Lys96 forms a hydrogen bond
through the Phe102 (H CDR3) main chain oxygen atom and is also involved in interactions
with a water molecule that is in the allergen–antibody interface. This water molecule is
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bound through hydrogen bonds with two neighboring water molecules, as well as with
Asp98 (L CDR3). Moreover, Lys96 is close (3.7 Å) to the carboxyl group of Asp104 (H
CDR3).
Substitution to Glu at position 96 was expected to perturb this hydrogen bond
network while also giving rise to unfavorable electrostatic repulsion with the negatively
charged carboxylate groups. Ile97 also forms a hydrogen bond through main chain atoms
with amide group of Asn52, which is not expected to be affected by the mutation (H CDR2)
and, in addition, interacts through the side chain and hydrophobic interactions with Asn31
(CDR1 from H chain) and Tyr54 (H CDR2). The Ile97Glu mutation also eliminated the large
aliphatic side chain of Ile97 that was wedged against CDR1 from H chain and H CDR2 and
was expected to significantly reduce the ability of this residue to form extensive
hydrophobic contacts. In summary, the mutation did not only result in substitution of a
hydrophobic amino acid with a hydrophilic residue, but also changed the charge from
neutral to negative.
Furthermore, according to the so-called hotspot hypothesis, only a few very specific
residues on the antigen–antibody interface within each paratope and epitope are critical for
antigen recognition and binding [34]. Site directed mutagenesis on epitope residues have
supported this hypothesis. Mutations of one, two, or three epitope residues significantly
reduced, or even abrogated antibody binding showing that only a few residues dominated
the energetics of the antigen–antibody interactions [26,29]. Reduction of antibody binding
is usually encompassed by a reduction in antibody binding affinity as measured by the KD
(the equilibrium dissociation constant between the antibody and its antigen) [29]. Our
previous research on mutations on the Der p 1 epitope showed a reduction in antibody
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binding by 10-1,000 fold (from nano-molar to micro-molar KD values) depending on the
number of mutations done and on the importance of the mutated residue for antibody
binding. However, generally, we observed an exponential decrease/increase of KD values
with each subsequent mutation [29]. Henceforth, all the mutations done for mAb 7A1 were
expected to show a reduction in IgE binding as demonstrated by a reduction in KD values
[26, 29].
1.19 SITE-DIRECTED MUTAGENESIS OF THE mAb 7A1 EPITOPE ON DER P 2
AND EFFECT OF EPITOPE MUTATIONS ON mAb 7A1 BINDING
Our collaborators, Dr. Anna Pomés and her group at Indoor Biotechnologies,
generated the Der p 2 mutants, evaluated the IgE binding affinities of the mutants and
compared them to the wild type allergen. Site-directed mutagenesis of the mAb 7A1
epitope on Der p 2 was performed using the QuickChange Site-Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, CA). Recombinant Der p 2.0103 wild type and
mutants were expressed in a methanol-inducible Pichia pastoris system and purified over
an mAb 7A1 or 1D8 affinity chromatography column, respectively. The allergens were
eluted with 0.1 M glycine and 0.15 M NaCl (pH 2.5) and concentrated and dialyzed in PBS
(Phosphate-Buffered Saline).
To evaluate IgE binding capabilities of Der p 2 mutants, direct binding of mAbs
7A1 and 1D8 to Der p 2 wild type and mutants was assessed using a direct antibody binding
immunoassay. The capacity of the two Der p 2 mutants to bind the mAb 7A1 was
completely abolished by the amino acid substitutions discussed previously as shown by
direct and inhibition binding assays (Figure 1.20). However, the ability of mAb 1D8
(whose epitope lies opposite from the mAb 7A1 epitope) to bind the mutants was preserved
(Figure 1.20A), suggesting that the overall fold of Der p 2 mutants was conserved. Similar
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folding of the mutants versus the wild type was confirmed by NMR (1D-NOESY)
performed by Dr. Mueller and his group. These results confirmed that the Der p 2 mutants
were properly folded and the reduction in IgE binding was due to the mutations, and not
improper folding of the protein.
IgE binding of the Der p 2 mutants compared with wild type was also tested using
patient blood plasma. IgE inhibition experiments were carried out by Dr. Anna Pomés and
her group at Indoor Biotechnologies; using plasma from five different patients acquired
from PlasmaLab International (Everett, WA), which operates in full compliance with Food
and Drug Administration regulations. Informed donor consent was obtained from each
individual prior to the first donation. The differences in the ability to inhibit plasma IgE
antibody binding to wild type Der p 2 between mutants and wild type were from 10-fold
up to 100-fold among the five patients. The data obtained from patient inhibition assays
confirmed a consistent decrease in IgE binding to the mutants versus the wild type (Figure
1.20B). Given that the human IgE antibody response is polyclonal, the mutations
performed were not expected to completely inhibit plasma IgE antibody binding, but only
affect the binding of those IgE that recognize a site overlapping with the mAb 7A1 epitope.
This decrease of IgE binding to the mutants could reflect partial or complete abolition of
binding of those IgE antibodies that overlap with mAb 7A1.
1.20 DISCUSSION
Allergens, supposedly harmless substances to most people, pose a major health
threat to more than one third of the world’s population [1]. These allergens stem from
various sources including pollens, food and other aeroallergens.

To exacerbate the

problem, there is also cross-reactivity between pollens, spices, food, and other structurally
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similar allergens giving rise to conditions such as pollen-food syndrome [10]. Allergies
are not only a nuisance, but an aggravator of conditions exemplified in asthma, atopic
dermatitis, and allergic rhinitis [15,17]. HDM allergens in particular, have been shown to
either exacerbate symptoms in asthmatic patients, or act as a trigger to the development of
asthma, atopic dermatitis and rhinitis. Up to 85% of atopic asthmatics are allergic to HDM
allergens in some regions [20]. Among major allergens from HDM, Group 1 and 2
allergens are recognized by IgE by more than 80% of sensitized individuals [20]. Studies
show that Group 1 and 2 mite allergens combined bind 50–70% of the IgE that recognizes
mite extracts [18]. Structural analysis of the IgE recognition of allergens is the basis for
rational design of recombinant counterparts to be used in the future for immunotherapy.
Previous studies by our group reported the structures of Group 1 HDM allergens,
Der p 1 and Der f 1, in complex with Fab of murine IgG mAbs [72-75]. These IgG mAbs
were used as surrogates for IgE antibodies because 1) they were reported to inhibit IgE Ab
binding to the allergen, which confirmed their epitope overlap with IgE binding site(s), and
2) they are homogeneous proteins, which is needed for crystallization purposes (unlike
serum IgE that is not possible to crystallize because of its polyclonal nature). This approach
allowed the determination of IgE antibody binding sites by detailed site-directed
mutagenesis analysis of the IgG epitope.
The recurrent crystallization of the 6A8 light chain dimer instead of a Fab, although
a surprising and quite disappointing result, emerging research suggest light chain dimer
formation is not as peculiar in human health and allergic diseases like asthma and rhinitis
[67]. In a normal setting, allergic rhinitis and asthma are deemed to share a unified disease
pathway mainly propagated by an inflammatory cell cascade involving Th2 cells which
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lead to the production of allergen specific IgE antibodies from activated B cell-derived
plasma cells. In retrospect, patients with allergic rhinitis and asthma have abundant mast
cells in the nasal mucosa [68]. However, research has shown that some non-allergic asthma
and rhinitis patients also show increased numbers of mast cells in their nasal mucosa,
supporting the perception that a cohort of nonallergic patients have an inflammatory-type
pathology, localized to the nasal mucosa. Further research unraveled an alternative IgEindependent pathway mediated by immunoglobulin free light chains (FLCs) [68].
In healthy individuals FLCs are produced in abundance compared to intact
antibodies. These FLCs have also been implicated to play a pivotal role in the pathogenesis
of other inflammatory and autoimmune diseases like rheumatoid arthritis, multiple
sclerosis, systemic lupus erythematosus and AIDS [67]. Several scientists have tried to
demystify the biological role of FLCs and their results show that these proteins are capable
of modulating the immune system and have the ability to bind antigens among other
functions [67,68,76]. Despite that monomeric FLCs can also bind antigens, the structural
features of dimeric FLCs resemble an antibody Fabs, therefore, the binding capabilities of
dimers prevail over that of monomeric FLCs [77].
Less attention, however, has been given to the analysis of the peculiar functional
properties of dimeric FLCs. Additional studies are needed to understand better the
pathophysiology of nonallergic rhinitis that is mediated by FLCs. Among these, further
studies are needed to identify which allergens can act as triggers in FLC-mediated mucosal
immune responses. Measurement of FLCs and secretory IgE in nasal secretions from
subjects with allergic and non-allergic rhinitis can be a good diagnostic method. Having
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noticed formation of FLCs in HDM allergy, like we experienced with Der f 1 mAb 6A8,
further research on the role FLC play in Group 1 HDM allergy are certainly warranted.
On a different note, to our knowledge, the current study on Group 2 HDM allergens,
published in the Journal of Immunology [26] reports the first X-ray crystal structure of one
of the most important major mite allergens, Der p 2, in complex with a murine IgG mAb
7A1. Structural analysis of the Der p 2.0103–7A1Fab complex demonstrated the flexibility
of Der p 2 upon antibody binding. Superposition of the X-ray crystal structures of Der p
2.0103 alone and in complex with the Fab of the mAb 7A1, revealed conformational
changes in the allergen structure upon antibody binding. Antibody binding to one part of
the allergen molecule was translated into conformational changes, even in distal parts of
the molecule opposite to the mAb 7A1 epitope, which could potentially affect the binding
of other antibodies. Nevertheless, either mAb 1D8 or αDPX could simultaneously bind Der
p 2 even when the allergen was already bound to mAb 7A1.
Overall, this study presented a detailed analysis of an IgE antibody binding site on
the HDM major allergen, Der p 2. This was achieved by determining the X-ray crystal
structure of Der p 2.0103–7A1Fab complex, combined with NMR studies. The epitope
recognized by the murine IgG mAb 7A1 (which had been reported to overlap with an IgE
antibody binding site on the allergen) was identified by studying the allergen-antibody
binding interface on the Der p 2.0103–7A1Fab complex. Detailed analysis of the epitope
defined critical residues for allergen-antibody interactions which led to a rational design of
site-directed mutagenesis experiments. The epitope structure and subsequent mutagenesis
analysis showed that residues 31, 33, 96, and 97 are important for IgE binding. These
residues are conserved across 15 Der p 2 and 16 Der f 2 isoforms currently listed in the
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Allergen Nomenclature database (www.allergen.org). Accordingly, the mAb 7A1
recognized all six variants tested: Der p 2.0101, Der p 2.0102, Der p 2.0103, Der f 2. 0101,
Der f 2.0102, and Der f 2.0103 [78]. Therefore, the relevance of these finding in terms of
design of hypoallergens could be extended to the cross-reactive allergen Der f 2 that is also
recognized by mAb 7A1.
In addition, Eur m 2, Lep d 2, and Tyr p 2 variants have at least 1-aa substitution at
one of the two positions mutated for each mutant, and these allergens are not recognized
by mAb 7A1 [78]. These differences are the basis for cross-reactivity or lack thereof among
group 2 allergens from different species [78]. Furthermore, when mAb 7A1 was used in
ELISA assays with patient blood sera, it was shown to inhibit up to 39% of plasma IgE
binding to Der p 2 for five mite-allergic patients, in agreement with an up to 30% inhibition
previously reported in individual or pooled patients’ sera [79]. This shows the importance
of mAb 7A1 epitope in human IgE binding. Overall, these findings indicate that mAb 7A1
would be a good candidate for measuring Der p 2 in complex extracts used for diagnosis
and immunotherapy, in contrast to other mAbs that do not recognize all the isoforms [80].
The identification of amino acid substitutions involved in IgE binding will allow for a
rational design of hypoallergens for better therapy, aiming to mitigate adverse reactions
that are usually observed in conventional immunotherapy.
1.21 FUTURE DIRECTIONS
Studies by Chapman et. al revealed a fundamental finding which suggest that sometimes
most epitopes defined by monoclonal antibodies derived from mice are not the same as, or
close to, those defined by human IgE antibodies [45]. These striking differences in the
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repertoires of murine IgG and human IgE antibody put into question the integrity of using
murine-derived mAb as surrogates in studying human IgE binding.
Future studies on this HDM project aim to use human-derived monoclonal IgE
antibodies instead of murine-derived IgG antibodies and promising preliminary results
have already been elucidated using human derived mAb 2F10 in complex with Der p
2.0103 produced by Dr. Pomés’ laboratory. For mAb 6A8, fusion proteins with leucine
zippers, known to form hetero-dimeric proteins, will be made in the quest to make Fabs for
crystallization and other assays.
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TABLES
Table 1.1: House Dust Mite Allergens

The 39 HDM allergens officially registered by the WHO/IUIS Allergen Nomenclature
Sub-Committee (www.allergen.org). Group 1 and 2 (Cysteine proteases and Niemann
Pick C2 family) are the allergens studied in this research.
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Table 1.2: IgE and IgG antibodies specific for Group 1 and 2 HDM allergens
Antibody

Type

Antigen

Progress

1C14

IgE-IgG

Der p 1

Unstable

E11

IgE scFab

Der p 1

Unstable

4C1

Fab

Der p 1

Crystallization

6A8

Fab, scFv

Der f 1

Light Chain Dimer
Structure

2G1

Full IgE

Der p 2

Crystallization

5D10

Full IgE

Der p 2

Crystallization

1B8

Full IgE

Der p 2

Crystallization

αDPX

Fab, scFv

Der p 2

Unstable

1D8

Fab, scFv

Der p 2

Unstable

7A1

Fab, scFv

Der p 2

Fab Structure Solved

2F10

Fab, Human IgE

Der p 2

Structure Solved

1B8

Fab, Human IgE

Der p 2

Unstable
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Table 1.3: Data collection, processing, and refinement
statistics for mAb 6A8 Light Chain Dimer
Diffraction source

APS Beamline 22ID

Wavelength (Å)

1.0000

Temperature (K)

100

Space group

C222

a, b, c (Å)

123.7, 132.6, 65.4

α, β, γ (°)

90.00, 90.00,90.00

Resolution range (Å)

40.00-2.80 (2.80-2.72)

No. of unique reflections

13125 (639)

Completeness (%)

95.6 (94.4)

Redundancy

3.4 (3.0)

〈I/σ(I)〉

12.5 (3.1)

Rmeasure

0.096(0.754)

Rp.i.m.

0.049(0.410)

Overall B factor from Wilson plot (Å2) 66.04
CC1/2

(0.692)

Rcryst

0.198 (0.247)

Rfree

0.259 (0.302)

R.m.s. deviations
Bonds (Å)

0.013

Angles (°)

1.6

Average B factors (Å2)

66

Ramachandran plot
Favoured (%)

98.1

Allowed (%)

1.9

Outliers (%)

0

Parameters for the highest resolution shell are in parentheses. ID,
identifier; R.m.s, root-mean-square.
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Table 1.4: Data collection, processing, and refinement
statistics for mAb 7A1-Der p 2.0103 Complex
PDB ID

6OY4

Diffraction source

APS Beamline 22ID

Wavelength (Å)

1.0000

Temperature (K)

100

Space group

C2

a, b, c (Å)

180.1, 43.3, 106.0

α, β, γ (°)

90.0, 125.3, 90.0

Resolution range (Å)

40.00-2.45 (2.49-2.45)

No. of unique reflections

23826 (1143)

Completeness (%)

94.7 (92.4)

Redundancy

3.0 (2.4)

〈I/σ(I)〉

14.5 (2.2)

Rmeasure

0.133 (0.547)

Rp.i.m.

0.074 (0.325)

Overall B factor from Wilson plot (Å2) 47.3
CC1/2

(0.628)

Rcryst

0.203 (0.257)

Rfree

0.260 (0.312)

R.m.s. deviations
Bonds (Å)

0.011

Angles (°)

1.4

Average B factors (Å2)

42.9

Ramachandran plot
Favoured (%)

97

Allowed (%)

100

Parameters for the highest resolution shell are in parentheses. ID,
identifier; R.m.s, root-mean-square [26].
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Table 1.5: Hydrogen bonds formed between
mAb 6A8 homodimer chains

1
2
3
4
5
6

Chain A
TYR 88
GLN 39
GLY 43
GLN 125
SER 95
TYR 88

Chain B
GLN 39
GLN 39
TYR 88
SER 117
ARG 47
GLY 43

Distance (Å)
3.2
2.8
2.7
2.9
2.6
2.8
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FIGURES

Figure 1.1: Project Flow Chart. The two main projects carried out in this research. Blue
side denotes the steps done for the HDM project and yellow for the profilins project
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Figure 1.2: Superposition of structures of Group 1 and 2 HDM Allergens. (A) Group
1 HDM allergens, Der f 1 (forest green; PDB: 5VPK) and Der p 1 (sand; PDB: 2AS8) share
81% sequence identity, and (B) Group 2 HDM allergens, Der f 2 (ruby; PDB: 1XWV) and
Der p 2 (deep teal; PDB: 1KTJ) share 88% sequence identity.
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Figure 1.3: HDM Project Flow Chart. The two sections in green boxes are parts done by
our collaborators, Dr. Anna Pomés and her group at Indoor Biotechnologies. Murine IgG
antibodies were obtained from hybridomas developed by Dr. Martin Chapman at the
University of Virginia. Human IgE constructs were isolated either from phage display
combinatorial libraries by Dr. Mats Ohlin at Lund University (Sweden), or from Dr. Scott
Smith at Vanderbilt University Medical Center using human hybridoma technology, as part
of the R01R01AI077653 project. All IgE constructs were expressed either in mammalian
cells or yeast Pichia pastoris at Indoor Biotechnologies.
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Figure 1.4: Der p 2.0101 and Der p 2.0103 Sequence Alignment and SDS-PAGE for
Der p 2.0101. (A) Sequence Alignment for Der p 2.0101 and Der p 2.0103 [81]. The two
isoforms share 98% sequence identity (B) SDS-PAGE for Der p 2.0101 after Ni-NTA
purification. The protein was obtained in monomeric form.
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Figure 1.5: SDS-PAGE after Ni-NTA purification of isoform Der p 2.0103 and SEC
Elution Profile. (A) SDS-PAGE after IMAC purification (B) SEC elution profile. The
protein was obtained in monomeric form. The yield was 7 mg/L of culture. Myoglobin and
vitamin B12 are shown as molecular weight standards.
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Figure 1.6: Schematic diagram of immunoglobulin E and immunoglobulin G.
(A) Immunoglobulin E, IgE and (B) Immunoglobulin G, IgG [82].
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Figure 1.7: Schematic diagram of antibody fragments. (A) Single chain variable
fragments-scFv (i) heavy chain first in sequence then linker then light chain (ii) light chain
linked to the N-terminus of heavy chain (B) Antibody fragment (Fab) Light chain and
heavy chain linked together by a disulfide bond.
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Figure 1.8: mAb 6A8 constructs generated over three years of research. Single chain
variable fragments (scFv) (A) Long Linker (GGGGS)x3 (B) Short Linker (GGGGS)x2.
(C) Antibody Fragment (Fab) with purification tag on both chains (D) Glutathione S
Transferase (GST) Fusion protein. Linker comprised of GGGS.
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Figure 1.9: SDS-PAGE after Ni-NTA purification of
mAb 6A8 scFv (short linker). Although the expression
and solubility of the protein was considerably enhanced,
the protein was very unstable. After SEC, the yield of the
protein was 1.5 mg/L of culture.
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Figure 1.10: SDS-PAGE after Ni-NTA purification of mAb 6A8 Fab and SEC Elution
Profile. (A) SDS-PAGE after IMAC purification. The light chain was overexpressed than
the heavy chain (B) SEC elution profile. The protein was obtained in monomeric form.
The yield was 6-8 mg/L of culture. Vitamin B12, Myoglobin and Ovalbumin are shown as
molecular weight standards.
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Figure 1.11: X-ray crystal structure of mAb 6A8 Light Chain Dimer. (A) Cartoon
presentation (B) Surface presentation. Chain 1 is sky blue and chain 2 is in firebrick.

55

Figure 1.12: Superposition of mAb 6A8 light chain dimer and a
kappa light chain dimer (PDB: 1B6D). mAb 6A8 is in sky blue and
1B6D in deep salmon. 6A8 light chain dimer has similar structural
features as other light chain dimers in the Protein Data Bank.
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Figure 1.13: X-ray crystal structure of mAb 6A8 Light Chain Dimer with
CDRs highlighted and distribution of B factors. (A) Surface presentation with
CDRs on top of the chains. Chain 1 is in sky blue and chain 2 is in firebrick. (B)
Overall B-factors- mobility of mAb 6A8 light chain dimer. Red color and the larger
diameter of ribbon correspond to the highest mobility/displacement of residues;
blue color and the smallest diameter correspond to regions with the lowest mobility.
Other colors and diameters of the ribbon indicate intermediate mobility of the
residues.
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Figure 1.14: SDS-PAGE after Ni-NTA purification of 6A8 LL dimer and Der p 2.0103
complex and SEC Elution Profile. (A) SDS-PAGE after SEC purification (B) SEC elution
profile. Peak 1 is mainly 6A8 LL dimer and peak 2 is mainly Der p 2.0103 with a little
amount of 6A8 LL dimer. Myoglobin and Vitamin B12 are shown as molecular weight
standards.
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Figure 1.15: ELISA Binding Assays of 6A8 LL dimer to several allergens. 6A8 LL
dimer binding to (A) Group 1 allergens (B) Group 2, Der p 2 and (C) random allergens and
non-allergens. 6A8 LL dimer is non-specific and binds to random proteins. These
experiments were performed by Dr. Anna Pomés and her group at Indoor Biotechnologies.
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Figure 1.16: Structure of Der p 2.0103–7A1Fab Complex. (A) Space filling
representation of the complex (top). Der p 2 is shown in magenta, whereas L and H chains
of the Ab are marked in light and dark gray, respectively. CDRs are mapped on mAb 7A1
molecular surface and marked with different colors (bottom). (B) Interaction between the
epitope and the paratope. Positions of water molecules buried between allergen and the Ab
are marked with red spheres. For clarity of the presentation, only positions of water oxygen
atoms are shown. (C) The inset shows the residues from epitope and paratope that are
involved in formation of H-bonds (green dashed lines) and a cation-p interaction (blue
dashed line) presented in stick representation. The color scheme is the same as in (A) and
(B) [26].
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Figure 1.17: Mobility of Der p 2 in the structure with the mAb 7A1 complex. (A)
compared with Der p 2 alone (B). Comparison of B factors between mAb 7A1 bound (A)
and free (PDB code: 1KTJ) Der p 2.0101 (B) Red color and the larger diameter of ribbon
correspond to the highest mobility/displacement of residues; blue color and the smallest
diameter correspond to regions with the lowest mobility. Other colors and diameters of the
ribbon indicate intermediate mobility of the residues. (C) Superposition of main chains for
mAb 7A1–bound (magenta) and –free (gray) Der p 2.0103. Ovals mark regions that display
the most pronounced conformation differences. (D) Display of Der p 2 residues in x-ray
crystal structures, associated with conformational changes of methyl residues in Der p 2
observed by NMR (see Fig. 3). The ribbon diagram of Der p 2 alone (1KTJ) is colored
green for residues that would interact with mAb 7A1, gray for other residues, and yellow
sticks are shown for Ile28, Leu61, Val63, and Ile97. Der p 2 in the mAb 7A1 Fab complex
is colored black, and Ile28, Leu61, Val63, and Ile97 are rendered with purple sticks. The
Fab is rendered in dark red with a ribbon and mesh surface. (E and F) Structural changes
of specific Der p 2 areas upon Ab binding. Magenta, Ab bound Der p 2.0103; gray, free
Der p 2.0103 (PDB code: 1KTJ). (E) Zoom on a region that was marked in (C) with the
smaller oval. (F) Comparison of conformation of the amino acids forming the mAb 7A1
epitope [26].
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Figure 1.18: Comparison of Tris and Phosphate Buffer in 7A1 scFv purification.
7A1scFv is more soluble in phosphate than tris buffers.
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Figure 1.19: SDS-PAGE after Ni-NTA purification and SEC Elution Profile of
isoform Der p 2.0101 and 7A1 scFv complex. (A) SDS-PAGE shows the successful of
co-expression of 7A1 scFv and Der p 2.0101. (B) The two proteins were in complex.
Hence, one elution peak was obtained in SEC. Myoglobin and Ovalbumin are shown as
molecular weight standards.
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Figure 1.20: Mutations abolished mAb 7A1 binding to Der p 2.0103. (A) Direct binding
assay showing that the two Der p 2 mutants in the epitope for mAb 7A1 did not bind
biotinylated mAb (B-mAb) 7A1, whereas both bound B-mAb 1D8 (positive control). Plot
represents an average of two experiments. (B) Reduced capacity to inhibit patient’s IgE
antibody binding by Der p 2 mutants versus the wild type. A reduction of the IgE Ab
binding in different degrees by the two mutants was seen for all patients. Plot represents
an average of three experiments (each run in duplicate) [26].
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CHAPTER 2
STRUCTURAL, FUNCTIONAL AND IMMUNOLOGICAL STUDIES OF
PROFILIN ALLERGENS FOR COMPONENT RESOLVED ALLERGY
DIAGNOSTICS AND IMMUNOTHERAPY1,2

2.1 BACKGROUND AND INTRODUCTION TO PROFILINS
Worldwide, there are thousands of allergens known to cause allergies and they
afflict more than one-third of the population [2]. These allergens are grouped into over a
hundred allergen families [3] and a significant fraction of officially registered allergens
originates from the profilin family of proteins. Profilins are ubiquitous proteins that were
discovered for the first time more than 40 years ago in calf thymus [85]. These small (12–
15 kDa) and typically eukaryotic proteins have been proven to be involved in regulating
various cellular processes including membrane trafficking, actin cytoskeletal dynamics, as
well as binding to proline-rich regions of proteins [85,86].
_____________________________________
1

Kapingidza A.B., Pye S.E., Hyduke N., Dolamore C., Pote S., Schlachter C.R., Commins
S.P., Kowal K. and Chruszcz M. 2019. Molecular Immunology. 114:19-29.
Reprinted here with permission of publisher.
Cudowska B., Kapingidza A.B., Pawłowicz M., Pampuch A., Hyduke N., Pote S.,
Schlachter C.R., Lebensztejn D.M., Chruszcz M. and Kowal K. 2020. Molecules. 25 (2):
369
Reprinted here with permission of publisher.
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Along with proteins like cyclophilins, nonspecific lipid-transfer proteins, and
polcalcins, profilins are also considered to be panallergens [10]. These pervasive proteins
share high sequence identity and similarity (Figure 2.1) and have extremely conserved
three-dimensional structures [87]. This explains why high IgE cross-reactivity is observed
among panallergens [9]. However, currently only plants and mites have been identified as
sources of allergenic profilins [9].
Plant profilins registered as allergens have high sequence identity (at minimum
65%), even between relatively distant related members such as weeds and fruits [88].
Allergenic plant profilins originate from pollens of weeds, trees, and grasses, in addition
to fruits, legumes, seeds and vegetables [10]. Therefore, profilins account for pollen-food
syndrome. Moreover, between 10–30% of patients allergic to pollen are also sensitized to
profilins [89,90]. Profilins have also been indicated as being responsible for food allergy
depending on sensitization to cross-reactive pollens in the mugwort-celery-spice syndrome
and ragweed-melon allergy [91,92]. A broad range of plant-derived food products contain
profilins including fruits, legumes, nuts, and vegetables [9]. It is commonly accepted,
however, that profilin-dependent allergic reactions to food result from cross-reactivity
between pollen and food profilins where the former are true sensitizers [93,94]. Although
some profilins can elicit adverse immune responses such as anaphylaxis, the infrequent
systemic reactions observed in patients after oral exposure to profilins is due to their low
stability and high susceptibility to denaturation by proteases in the acidic environment of
the digestive tract [83,95].
Although several other profilins were characterized in this research, Cuc m 2.0101,
a profilin from Cucumis melo (muskmelon), Art v 4.0101 a profilin from Artemisia vulgaris
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(mugwort) and Phl p 12.0101, a profilin from Phleum pratense (Timothy grass), will be
discussed herein. Despite a majority of the allergenic profilins being considered as minor
allergens, [89] Cuc m 2.0101 can elicit IgE production in 80% of muskmelon allergic
patients. As such, Cuc m 2.0101 is regarded as a major allergen [96]. Muskmelons are
found throughout the world and are commercially grown in Turkey, the USA, Spain,
Morocco, India and other countries [97]. Cuc m 2 is one of the most important melon
allergens, and in general, melon allergy is one of the most common food allergies [98].
Food allergies are characterized by symptoms in the skin, gastro-intestinal tract, and
respiratory system, resulting in oral itching, lip swelling, and labial edema, or [99]. Cuc m
2, specifically, primarily elicits oral itching and lip swelling symptoms [100].
On the other hand, Artemisia vulgaris, known colloquially as mugwort, is another
known source of profilins. It is a member of the Asteraceae family found in temperate
regions of the northern hemisphere, the Mediterranean basin, and parts of Asia [101].
Patients with mugwort sensitivity often experience ragweed sensitivity as a result of corecognition of the major allergens from each plant rather than cross-reactivity of common
antigens [101]. It is noteworthy that A. vulgaris is one of the few important allergenic
sources causing allergic diseases in 10–14% of pollinosis (pollen allergy) patients
[102,103]. Art v 4.0101, an A. vulgaris profilin, is a clinically significant weed allergen
[88] that has a sensitizing prevalence of 34–36% in Europe [104].
The third profilin studied, Phl p 12.0101, stems from Timothy, a perennial grass
native to most of Europe and found in most of the United States [84]. Due to this ubiquitous
nature of Timothy grass, it is a potent source of allergens for many sensitized patients.
Despite Phl p 12.0101’s characterization as a minor allergen, it displays comparable T cell
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response prevalence and strength as Phl p 1, a major allergen from Phleum pratense [105].
In addition, it is released from Timothy grass pollen in the same timeframe as the other
Timothy grass allergens and in similar amounts as Phl p 1 [105]. Phl p 12.0101 also has
high sequence identity (76 %) to Cuc m 2.0101 and the potential for cross-reactivity
between the two profilins is high [9].
In this research, the structural, molecular, and thermal stability characteristics, as
well as, possible IgE cross-reactivity between profilins was investigated. Firstly, the
recombinant versions of the three profilins were expressed in E. coli and two of the proteins
were crystallized. Secondly, to develop new insights into the allergenicity of profilins, the
thermal stability of this family of proteins was compared using Differential Scanning
Fluorimetry (DSF). The combination of structural and thermal stability studies offers
explanations for the molecular basis of various clinical syndromes observed involving
profilins (Figure 2.2). Lastly, Art v 4.0101 and Phl p 12.0101 were tested for their ability
to bind patient-derived antibodies to establish sensitizing patterns in children and adult
patients from North-East Poland—a region abundant in birch, timothy grass, and mugwort,
but with no ragweed. Studying the molecular and immunological characteristics of Cuc m
2.0101, Art v 4.0101 and Phl p 12.0101 will clarify the clinical relevance of these important
profilins in allergy sensitization and their possible contribution to pollen-food syndrome.
Comparison of profilins molecular, structural and antigenic properties provides new
insights into the allergenicity of this family of proteins, expedite allergy diagnostics and
facilitate the development of hypoallergenic molecules that can be exploited in
immunotherapy.
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2.2 PRODUCTION OF RECOMBINANT PROFILINS CUC M 2.0101, ART V
4.0101AND PHL P 12.0101
Genes coding for Cuc m 2.0101 and Art v 4.0101 were synthesized and inserted in
pJExpress411 plasmid by DNA 2.0 (currently ATUM, Newark, CA). Phl p 12.0101 was
synthesized and inserted in pET26b (+) plasmid by Bio Basic (Amherst, NY, USA). The
inserts

were

designed

with

a

cleavable

N-terminal

purification

tag

MHHHHHHSSGVDLGTENLYFQ/SGSG, where the slash denotes the Tobacco Etch
Virus (TEV) protease cleavage site. The plasmids were transformed into E. coli BL21(DE3) or BL-21 (DE3) pLysS cells in the case of Cuc m 2.0101. Cultures were grown
in LB with 50 μg/mL kanamycin at 37 °C to an OD600 of 0.4. Cultures were then cooled to
22 °C and grown to an OD600 of 0.8 and induced with IPTG at a final concentration of 0.5
mM, cooled to 16°C, and grown for 16–18 hours. Cell pellets were resuspended in lysis
buffer (50 mM Tris−HCl, 500 mM NaCl, 2% glycerol, 20 mM β-mercaptoethanol (β-ME),
10 mM imidazole, pH 7.4) and lysed by sonication. The sonicated mixture was centrifuged
at 9000 x g for 10 min at 4°C. The supernatant was loaded onto a Bio-Rad Econo-Pac
chromatography column containing Thermo- Scientific HisPur Ni-NTA resin equilibrated
with the same lysis buffer. The protein was eluted using elution buffer (50 mM Tris−HCl,
50 mM NaCl, 2% glycerol, 20 mM β-ME, 250 mM imidazole, pH 7.4). Elutions containing
protein were determined by SDS-PAGE, pooled and dialyzed overnight using Pierce
SnakeSkin Dialysis Tubing with a molecular weight cutoff of 3,500 Da and dialysis buffer
(50 mM Tris−HCl, 150 mM NaCl, pH 7.4). The dialyzed proteins were concentrated using
a Millipore Amicon Ultra concentrator with a 3,000 Da molecular mass cutoff and was
further purified by SEC using a GE Healthcare ÄKTA-Pure FPLC and HiLoad Superdex
200 column.
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The proteins were observed to be predominantly monomeric based on SEC results
(Figure 2.3). However, a small fraction of the produced protein was present in a dimeric
form. Due to the small amount of the produced dimeric form, only the monomeric form of
the protein was studied further. Fractions containing the monomeric protein were
concentrated and protein concentration was determined spectrophotochemically measuring
absorption at 280 nm using a Thermo-Scientific Nanodrop. TEV protease was used to
cleave the purification tag from the profilins according to the protocol previously described
[106]. For crystallization experiments, the proteins (stored in 50 mM Tris−HCl, 150 mM
NaCl, pH 7.4) were concentrated to 12, 25 and 40 mg/mL. The concentration was measured
spectrophotochemically at 280 nm using a Thermo-Scientific Nanodrop [83]. The yield of
the profilins were as follows: Phl p 12 - 70mg/L, Cuc m 2 - 40mg/L and Art v 4 - 25mg/L
of culture. The proteins were used for circular dichroism to ensure proper folding, thermal
stability studies using DSF, crystallization experiments, and sensitization studies using
patient blood sera.
2.3 CIRCULAR DICHROISM SPECTROSCOPY (CD)
The three-dimensional structure of an allergen plays a crucial role in its function
and allergenicity [34]. To test folding of the proteins in their native form, circular
dichroism, which estimates the secondary structure of a protein, was employed. In addition,
although the X-ray crystal structure for Cuc m 2.0101 was eventually obtained, no
diffracting quality crystals have been obtained for Phl p 12.0101 to date; hence, the
secondary structure of the proteins (with purification tag intact for Cuc m 2 and without
purification tag for Phl p 12) had to be estimated using circular dichroism spectroscopy
(JASCO spectrophotometer). An X-ray crystal structure for Art v 4.0101 had already been
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obtained. Protein samples for CD experiments were desalted using Sephadex® beads
previously equilibrated in 10 mM sodium phosphate buffer that had been adjusted to pH
7.4 using phosphoric acid. The samples were concentrated to 40 μM following the same
method mentioned previously. The instrument was operated according to the
manufacturer’s protocol at a wavelength range of 220–320 nm. Data processing was done
using CAPITO software and the secondary structure percentages were calculated [107].
For comparison purposes we used the Cuc m 2.0101 structure elucidated here (PDB code
6MBX) and secondary structure definitions assigned by DSSP software [61].
Cuc m 2.0101 (with purification tag) secondary structure was estimated as follows:
α-helices 0–27%, β-strands 30–48% and loop regions (irregular) 43–58% [107]. These
results are in agreement with the secondary structure calculated using the crystal structure
of Cuc m 2.0101 reported here (α-helices 24%, β-strands 35% and loop regions (irregular)
41%) [83]. The secondary structure of Phl p 12.0101 too was estimated by CAPITO to be
as follows (according to similarity hits based on 25 nearest neighbors): α-helices 9–16%,
β-strands 32–48%, and loop regions (irregular) 42–58% [107]. These results are similar to
the secondary structure calculated using the crystal structure of Cuc m 2 [83,84]. This data
strongly suggests that both recombinant Cuc m 2 and Phl p 12 were properly folded.
2.4 THERMAL STABILITY OF PROFILINS: DIFFERENTIAL SCANNING
FLUORIMETRY (DSF)
Differential scanning fluorimetry was used to investigate the thermal stability of
Cuc m 2.0101, Art v 4.0101 and Phl p 12.0101 with and without purification tag. DSF
experiments were carried out using Bio-Rad CFX96 RT-PCR instrument. All solutions
were made as an in-house salt gradient and pH screen. A working concentration of 50 mM
for the buffer was used for all the conditions with a pH range of 4.0−9.5 (in 0.5-unit
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increments) and a salt range (sodium chloride) 0−1.0 M (no salt, 0.05, 0.10, 0.15, 0.20,
0.25, 0.50, and 1.0 M). All experiments and steps were done according to the procedures
described previously [106]. To determine the melting temperatures of the profilins in each
condition, Bio-Rad CFX Manager software was used to calculate the inflection point of the
melting curves. Each experiment was performed three times and an average melting
temperature (Tm) was calculated [83,84].
Since the melting temperatures for all the 63 allergenic profilins could not
experimentally tested, theoretical melting temperatures for these profilins were calculated
with Tm Predictor [108]. To identify allergenic profilins and obtain amino acid sequences
that correspond to the mature forms of the proteins to use in the Tm Predictor, a search was
performed using the Allergome and AllFam software (Table 2.2) [3,109]. Allergen.org was
used to identify officially registered allergens [7].
The results for the DSF experiments performed for Cuc m 2.0101 (Figure 2.4) show
that the maximum melting temperature (56°C) is similar to those observed for previously
characterized Amb a 8.0101 (profilin from ragweed), Art v 4.0101, and Bet v 2.0101
(profilin from birch) [106]. From the melting temperatures acquired, Cuc m 2.0101 with
the purification tag was slightly more stable than with the cleaved tag. The salt
concentration did not have a major impact on Cuc m 2.0101 thermal stability, with the only
exemption being pH 4.0 for the protein with the purification tag. In comparison with Amb
a 8.0101, Art v 4.0101 and Bet v 2.0101 (birch profilin) studied previously [106], the
muskmelon profilin is significantly more stable in solutions with lower pH values. For
example, when Cuc m 2.0101 is compared with Art v 4.0101, the muskmelon protein is
clearly more stable in the 4.0–6.0 pH range, and the differences are especially pronounced
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in solutions with pH between 4.0 and 5.0. In these conditions, Cuc m 2.0101 has melting
temperatures 8–19°C higher in comparison with Art v 4.0101 (Figure 2.4B), Amb a 8.0101,
and Bet v 2.0101. The biggest differences are observed for solutions with pH 4.0.
For the thermal stability of Phl p 12.0101, the DSF results performed show that the
protein without purification tag was more stable with Tm difference as high as 6ºC than
with the tag intact (Figure 2.5). Both versions of the protein, however, are most stable
between pH 5.0 to 8.5 and least stable between pH 4.0 to 4.5. Salt concentration does not
have a major impact on Phl p 12.0101 thermal stability, with the only exemption being
seen at 1 M NaCl for the protein with the purification tag. Generally, in comparison with
Art v 4.0101, Bet v 2.0101 and Amb a 8.0101, Phl p 12.0101 without purification tag is
more stable than the other two profilins (Figure 2.5B-D). Comparison of the DSF results
between Cuc m 2.0101 and Phl p 12.0101 shows that the stability of Phl p 12.0101 is the
most similar to Cuc m 2.0101 than all the other profilins studied.
However, the timothy grass profilin is significantly more stable in solutions with
lower pH values both with and without the purification tag. For example, when Phl p
12.0101 is compared to Art v 4.0101, Cuc m 2.0101 and other profilins studied [84], the
protein is clearly more stable in the 4.0 to 6.0 pH range, and the differences are especially
pronounced in solutions with pH between 4.0 and 5.5. In these conditions, Phl p 12.0101
has Tm 7-26°C higher in comparison with Cuc m 2.0101, Amb a 8.0101), Art v 4.0101 and
Bet v 2.0101 (Figure 2.5B-D). The biggest differences were observed for solutions with
pH range 4.0 to 5.0. On the other hand, Phl p 12.0101 with the purification tag was nearly
as stable as the other three profilins from pH 7.0 to 9.5. Interestingly, at 1 M salt
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concentration, Phl p 12.0101 with purification tag was significantly less stable than Amb a
8.0101, Art v 4.0101, and Bet v 2.0101 with Tm difference as high as 11ºC (Figure 2.5D).
To compare the thermal stability of profilins, a computational approach was used
as described by Ku et al. [108]. This approach allowed to divide allergenic profilins into
three categories (Table 2.2). The first category includes proteins that have a predicted
melting temperature above 65°C, and only one profilin (Vit v 4, grapevine) was predicted
to belong to this group. The second category includes proteins melting in the 55–65°C
range, and there are several allergenic profilins predicted to be in this group (Cap a 2 (bell
pepper), Citr l 2 (watermelon), Cor a 2 (hazel), Cuc m 2 (muskmelon), Gly m 3 (soybean),
Mal d 4 (apple), Par j 3.0201 (pellitory of the wall), Pha v 5 (bean), Pru av 4 (cherry), Pru
du 4 (almond), Pru p 4 (peach), Sola l 1 (tomato), Sola t 8 (potato) and Tyr p 36 (storage
mite)). The third and most numerous group includes profilins that have melting temperature
predicted to be below 55°C. The predicted melting temperatures agree with the
experimental results for Amb a 8.0101, Art v 4.0101, Bet v 2.0101 and Cuc m 2.0101 [106].
In summary, our findings support the same conclusion as alluded to by other researchers
who classified profilins as labile proteins [110-112] and this might explain why most of
these profilins are regarded to as minor allergens. Thermal stability studies of profilins help
explain the molecular basis of the allergenicity of these group of allergens, however,
structural studies were still needed to decipher the influence of profilins structure in both
IgE cross-reactivity and immunogenicity.
2.5 CRYSTALLIZATION OF CUC M 2.0101 AND ART V 4. 0101
Crystallization of Cuc m 2.0101 was performed at 277 K. The best quality crystals
for both Cuc m 2.0101 (with purification tag) and Art v 4.0101 (cleaved purification tag)
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were grown using the sitting drop vapor diffusion method. The best diffracting Cuc m
2.0101 crystals were obtained when 40 mg/mL protein sample was mixed 1:1 with well
solution containing 2.8M sodium acetate, pH 7.0. Prior to data collection, Cuc m 2.0101
crystals were cryo-protected using 50% glycerol solution, then immediately cryo-cooled in
liquid nitrogen. Art v 4.0101 was crystallized at 293 K in MRC 2-drop 96-well
crystallization plates (Molecular Dimensions) by mixing 0.49 M sodium phosphate
monobasic pH 6.9 (Hampton Research Index Screen) with recombinant protein in a 1:1
ratio.
2.6 DATA COLLECTION AND STRUCTURE DETERMINATION
Data for the new crystal form of Art v 4.0101 was collected remotely using the
Southeast Regional Collaborative Access Team (SERCAT) 22-ID beamline at the
Advanced Photon Source (APS), Argonne National Laboratory. Data for Cuc m 2.0101
was collected at the 19-BM beamline of the Structural Biology Center, APS. Diffraction
images of each protein were processed with HKL-2000 [113]. The structures of Cuc m
2.0101 and Art v 4.0101 were solved by molecular replacement using MOLREP [53] and
HKL-3000 [52] with the previously published structure of Art v 4.0101 (PDB code 5EM0)
as the starting model [88]. The models were rebuilt using BUCCANEER [54] and COOT
[58]. The structures were refined using REFMAC [56] and HKL-2000. Various programs
from the CCP4 package [57] were used for data analysis. COOT and MOLPROBITY [59]
were used for validation of models. Both structures together with structure factors were
deposited into the Protein Data Bank [114] with accession codes 6B6J and 6MBX for Art
v 4.0101 and Cuc m 2.0101 models, respectively.
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2.7 STRUCTURAL ANALYSIS OF CUC M 2.0101 AND ART V 4.0101
The Cuc m 2 crystal structure was determined at 2.4 Å (PDB code 6MBX). Cuc m
2.0101 (155 amino acid residues – including the N-terminal purification tag) crystallized
in the C2 space group with three molecules in the asymmetric unit (Table 1). The crystal
structure could be also solved in P3221 space group (one molecule in the asymmetric unit);
however, in this case, the refinement and model update were not able to reduce the R free
value below 35%. Residues corresponding to the purification tag were not visible in the
electron density map and absent from the final model. Similar to other allergenic profilins,
like Art v 4.0101 (Figure 2.6), Cuc m 2.0101 also exhibits a crystal structure with three αhelices and seven-stranded antiparallel β-strands. Interestingly, Cuc m 2.0101 with the
cleaved tag crystallized as well, and the crystals were isomorphous (had very similar unit
cell parameters and the same symmetry) to those formed by protein with the purification
tag. However, their diffraction quality was poor, and their structural analysis was not
pursued.
The structure of a new crystal form of Art v 4.0101 was determined at 1.9 Å (PDB
code 6B6J). The protein crystallized in the P31 space group with one molecule in the
asymmetric unit. The previously determined Art v 4.0101 structure (PDB code 5EM0) was
derived from an orthorhombic form of the protein (P21212 space group). Both Art v 4.0101
structures superpose with RMSD value of 0.5 Å over 133 aligned Cα carbons which
illustrates highly similar conformations of the protein main chain. The overall structure is
similar despite the fact that the protein structures were obtained from crystallization
conditions that differed in pH (8.5 for 5EM0 and 6.9 for 6B6J reported here). Both Art v
4.0101 and Cuc m 2.0101 used for crystallization were monomeric in solution and in their
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crystal forms. On the other hand, however, previous studies have shown that natural and
recombinant Art v 4 can form dimers and tetramers that exhibit increased allergenicity and
are stabilized by intermolecular disulfide bonds or ionic interactions [115]. Furthermore,
Amb a 8.0101, Hev b 8, Zea m 12, and several others are reported to be present in
monomeric or dimeric states [116]. In the case of Hev b 8 and Zea m 12, the dimer
formation is also associated with creation of an intermolecular disulfide bond. This
covalent bond is formed between Cys13 from two different molecules [116]. Art v 4 has
three cysteine residues (Cys13, Cys95 and Cys117) and structural data indicates formation of
an internal disulfide (SS) bridge between Cys95 and Cys117 (Figures 2.6 and 2.7). Such an
SS bridge is not observed in Cuc m 2, despite having two cysteines (Cys13 and Cys115).
Interestingly, two different crystal structures with Cys13 and Cys117 oxidized or reduced
were reported for Bet v 2 [117].
Over 60 allergenic proteins analyzed (Table 2.2), only thirteen of them (Aca f
2.0101, Ama r 2.0101, Ama v 2.01, Ama v 2.02, Amb a 8.0101, Art v 4.0101, Art v 4.0201,
Hel a 2.0101, Koc s 2.0101, Pro j 2.0101, Sal k 4.0101, Sal k 4.0201 and Vit v 4) have
conserved Cys95 and Cys117 (based on Art v 4.0101 residue positions). We predict that all
these profilins most likely will have an intramolecular disulfide bridge formed by the Cys95
and Cys117. Interestingly, all of the analyzed allergenic profilins have conserved Cys13 and
Cys117. We also presume that all these allergenic profilins can possibly form dimeric
assemblies that were described for Hev b 8, which involve formation of a disulfide bridge
between two Cys13 residues from different molecules [116]. In this research, with Cuc m 2
and Art v 4, the formation of dimeric proteins was also observed although they were in
very small amounts compared to monomeric protein. Formation of dimeric proteins has
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been shown to influence IgE binding [115,116]. To demonstrate how formation of dimeric
proteins will influence IgE binding for Cuc m 2 using structural studies, IgE epitopes were
mapped on the Cuc m 2 experimental model and compared to the dimeric crystal structure
of Hev b 8.
2.8 IgE EPITOPES
Profilins represent one of the most numerous allergen families associated with
many clinical syndromes. Some of them, (Cit s 2, Citr l 2, Cuc m 2 and Gly m 3) being
major allergens, have instigated many researchers to investigate IgE epitopes associated
with these proteins [118,119,96,120]. In a study to characterize IgE epitopes of Cuc m 2
by López-Torrejón and colleagues, four IgE epitopes of Cuc m 2 were described (Figure
2.8) [121]. Two of these epitopes were defined as major (E1 – residues 66–75 and 81–93;
E2 – residues 95–99 and 122–131), because they showed the strongest IgE-binding
capacity, and two additional epitopes (E3 – residues 2–10; E4 – residues 35–45) showed
low

IgE-binding

capacity.

Later,

another

sequence

was

identified—

S2W3A5Y6D9H10T111P112 G113Q114N116M117R121L122 as forming a Cuc m 2 mimotope
(Figure 2.8) [89]. These studies were used to design Cuc m 2 mutants with reduced IgEbinding capacities [89]. Interestingly, the mimotope overlaps mainly with epitope E3
(Figure 2.8) and a significant area of the mimotope does not correspond to any of the
identified IgE epitopes.
Using structural studies, Cuc m 2 (surface representations) was superposed on one
of the molecules forming the Hev b 8 dimer which demonstrated that formation of a dimeric
structure would interfere with IgE biding to epitopes E2 and E3, as well as to the mimotope
(Figure 2.9). The formation of dimeric assemblies for Cuc m 2, Art v 4 and all other
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profilins is interesting not only in research but has important implications in allergy
sensitizations. Lastly, as mentioned before, profilins are involved in several clinical
syndromes including pollen-food syndrome. To observe sensitization patterns of profilins
and their possible role in pollen-food syndrome, sensitization studies were carried out in
100 patients with an established record of sensitization to pollen and plant-derived food
allergens.
2.9 SELECTION OF PATIENTS AND ANTIBODY BINDING STUDIES
This part of the research was carried out by our collaborators Dr. Kowal and his
group at the Medical University of Bialystok and the results were published in Molecules
[84]. However, all the assays were performed using recombinant profilins produced in the
Chruszcz laboratory. One hundred allergic patients, including 50 children and 50 adults
sensitized to pollen and plant-derived food allergens, were included. Patients with parasitic
infection, autoimmune and systemic diseases, chronic respiratory diseases of non-allergic
background, or immunosuppressive therapy were excluded from the study. Prior to the
study, none of the patients had undergone treatment using allergen immunotherapy. This
immunotherapy operated through the assessment of specific IgE (sIgE) antibodies’
interaction with individual allergen sources using a multiparameter immunoblot polycheck
(Biocheck, GmbH, Münster, Germany) according to the manufacturer’s protocol [84]. All
sera were tested for IgE reactivity to a panel of recombinant pollen profilins Amb a 8.0101,
Art v 4.0101, Bet v 2.0101, and Phl p 12.0101 which previously had been structurally and
immunologically characterized [88].
Sensitization to profilins was demonstrated in 9 P+ among 50 studied children
(18%) and 11 P+ among 50 studied adults (22%) with the “P+” designating an allergic
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reaction to the profilin. The prevalence of sensitization to profilins in our population was
similar to that reported previously in other populations of patients suffering from pollen
allergy [122-124]. In each P+ patients, IgE reactivity to all four studied profilins (Amb a
8.0101, Art v 4.0101, Bet v 2.0101, and Phl p 12.0101) was found (Figure 2.10).
Sensitization to each profilin detected in each P+ patient reflected high structural
similarities and immune cross-reactivity among plant-derived profilins (Figure 2.11) [88].
However, in a majority of patients sensitized to profilins, the greatest intensity of IgE
binding was demonstrated for Phl p 12.0101 with 7 of 20 (35%) P+ patients and Art v 4 in
6 of 20 (30%) P+ patients [84].
2.10 DISCUSSION
Profilins are proteins defined by their pervasive and abundant nature as well as their
high IgE cross-reactivity, by definition of a panallergen. These proteins share very high
sequence similarity and identity even among distantly related sources [87]. Due to this,
profilins are important players in allergen cross-reactivity. Although usually denoted as
minor allergens, profilins can sometimes be recognized by IgE by more than 50% of a
cohort of profilin sensitized patients [10]. Cuc m 2, a profilin from muskmelon, is
recognized by IgE in more than 80 % of sensitized individuals and is one of the most
important melon allergens with melon allergy being one of the most common food allergies
[98]. Melon allergy has been indicted as eliciting several cross-reactions with birch,
ragweed, and Timothy grass [9]. One such potentially cross-reactive profilin with Cuc m
2 is Phl p 12 from Timothy grass. Phl p 12 is a minor allergen that shares 76% amino acid
identity with Cuc m 2. Thus, chances of cross-reactivity between the two allergens is high.
Not only does Phl p 12 share high sequence identity with a major food allergen, but it also
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exhibits comparable T cell response frequency and strength as Phl p 1, a major allergen
also from Timothy grass. To exacerbate the situation, Phl p 12 is released simultaneously
and in the same amount as Phl p 1 [105].
The molecular, structural, and immunological properties of Cuc m 2, Art v 4 and
Phl p 12 were investigated. Although there are reports that some profilins are able to
assume several oligomeric states, both Cuc m 2 and Phl p 12 were expressed and purified
as primarily monomeric [115]. The thermal stability of profilins plays a major role in their
allergenicity; generally, profilins are known as thermally labile. DSF experiments for both
Cuc m 2 and Phl p 12 showed the profilins’ intrinsic thermal instability. Both Cuc m 2 and
Phl p 12 had the highest melting temperature at 56°C. This might explain why most
profilins are minor allergens since some of them, in particularly food allergens, have to go
through high temperature food processing. However, Cuc m 2 is recognized as a major
allergen perhaps due to the fact that melons are usually eaten raw.
Results of the maximum melting temperature predictions for the allergenic profilins
are consistent with our experimental data, and indeed they show almost all profilins being
thermally labile (Table 2.2). Predicted, relatively high melting temperature (> 65°C) for
Vit v 4 will require an experimental confirmation. Predictions of thermal stability also
show that there may be a subgroup of more stable allergenic profilins (melting in the 55–
65 °C range). This subgroup includes not only Cuc m 2.0101, but also Citr l 2.0101 and
Gly m 3.0101, major allergens originating from watermelon and soybean, respectively.
Interestingly, both DSF and melting temperature predictions indicate the presence of
internal disulfide bridges are not critical for profilin stability. This is supported by our
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experimental results showing that Art v 4 and Cuc m 2 have a similar maximum thermal
stability, despite the Tm Predictor classifying the Art v 4 as less stable.
Structural studies reveal that Art v 4.0101 and Cuc m 2.0101 have similar main
chain conformations as well, which reflects 80% sequence similarity and 70% sequence
identity. The experimental structures of the two afore mentioned proteins, together with
structures reported for Amb a 8, Ara h 5, Bet v 2, Hev b 8 and Zea m 12, provide insight
into molecular properties of allergenic profilins. The intramolecular disulfide bridge is not
critical for maintaining proper folding for the profilins. In addition, there are no significant
changes in the structure of these molecules in the presence or absence of the disulfide
bridge [83]. Analysis of recent profilin structures provides a more elaborate picture of
possible quaternary assemblies which may be present in this group of proteins. In the case
of recombinant Hev b 8, the formation of the dimeric assembly resulted in an increase of
IgE-mediated degranulation of rat basophilic leukemia cells [116]. Comparison of
monomeric structure of Cuc m 2 and the dimeric structure of Hev b 8 highlight implications
of the dimer formation (Figure 2.9). For example, it is clear that the dimer formation would
partially block residues forming epitopes E2 and E3 determined by López-Torrejón et al.
(Figure 2.9A) and completely block the mimotope found by Tordesillas et al. (Figure
2.9D). However, the studies of Cuc m 2 epitopes and the mimotope show the existence of
IgE antibodies having the ability to recognize residues part of a Cuc m 2.0101 dimerization
interface.
As alluded to by the Hev b 8 example above, the oligomerization state of a profilin
appears to play a major role in IgE response. This prompts a question about the
oligomerization state of natural profilins and their quaternary form(s) to which the human
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body is exposed, and what differences in IgE response these states elicit. It is also worth
noting that the residues forming the 674 Å2 dimer interface in Hev b 8 are almost
completely conserved in Cuc m 2.0101 (Figure 2.9D), and this is also true for Art v 4.0101.
Critics concur that the oligomerization of profilins warrants further research and may have
various biological implications [125]. Moreover, profilins are involved in a plethora of
molecular interactions, some involving the binding to proline-rich regions of various
proteins [126]. Comparison of the dimeric structure of Hev b 8 with model of Amb a 8 in
complex with polyproline (Figure 2.9B) implicates profilin dimerization also limits the
ability of the protein to interact with the proline-rich peptides due to the oligomerization
interface and the peptide binding sites partial overlapping. Conversely, the presence of both
monomeric and dimeric forms of a profilin could be a meticulous solution that can be used
in cells to modify affinity of the protein to various binding partners. Currently, how the
structure of tetrameric assemblies reported for Art v 4 is also not known [115]. It is possible
that the tetramer may be considered as a dimer of covalently linked dimers, as it was
determined for Hev b 8.
For the allergen sensitization studies of profilins, sensitizations to all studied
profilins detected in each patient (n=100) reflected high structural similarities and immune
cross-reactivity among plant-derived profilins. In a majority of patients sensitized to
profilins, the greatest intensity of IgE binding was demonstrated by Phl p 12.0101. It has
been proposed that sensitization to profilins depends on the intensity of exposure to
individual allergen sources with grass pollen being the most important [127]. However, in
some populations of birch and grass allergic patients, the frequency of sensitization to
profilins in those allergic to birch was greater than to grass pollen [124,128]. Interestingly,

83

in those populations from central Europe, sensitization to profilins was more frequently
observed in children than in adults. Furthermore, there appears to be a correlation between
age and profilin sensitization as exemplified by a longitudinal study of molecular spreading
of sensitization to individual allergens in timothy grass. The allergic children demonstrated
that binding of IgE to profilins occurs late and usually after sensitization to major allergens
such as Phl p 1 and Phl p 5 is well developed [129]. The greatest frequency of sensitization
to profilins was not achieved earlier than 5 years after the onset of clinical symptoms [129].
Similar observations concerning age and sensitization to profilins was made in a large
population of Italian children with allergic rhino conjunctivitis [122].
The above-mentioned findings support our results. In this research, no association
between clinical symptoms of pollen-allergy syndrome and sensitization to profilins could
be found. This indicates that sensitization to profilins was not necessary for development
of pollen-food syndrome in young children. Moreover, these findings indicate the
syndrome should be dependent on sensitization to other cross-reacting allergen
components such as pathogenesis related protein family (PR-10) allergens. In summary,
this study demonstrated that the presence of IgE for profilins in patients with pollen-food
syndrome is quite frequent. However, no clinical significance of that sensitization among
patients living in the area where birch pollen is a dominant tree allergen source could be
demonstrated. Ragweed is not present in North-East Poland, but reaction to Amb a 8.0101
was observed. This is caused by the high sequence and structure similarity between the
profilin originating from ragweed and other studied profilins. Further studies are warranted
to clarify the role of individual allergen sources in the process of sensitization to individual
proteins among allergic patients exposed to different aeroallergens.

84

2.11 FUTURE DIRECTIONS
After much deliberation, our findings reiterate the same results obtained previously
by other researchers that profilins are thermally labile. However, in the results presented
herein for the predicted thermal stabilities, there are profilins such as Vit v 4 (T m >65 °C)
which were predicted to be relatively stable compared to all other profilins. These melting
temperatures will require an experimental confirmation. Additionally, through structural
studies we predicted that all profilins that have conserved Cys95 and Cys117 (based on Art
v 4.0101 residue positions) will have an intramolecular disulfide bridge. Experiments must
be performed to substantiate this prediction.
Furthermore, we presume that all analyzed allergenic profilins with conserved
Cys13 and Cys117 have potential to form dimeric assemblies, as observed for Hev b 8, which
involves formation of a disulfide bridge between two Cys13 residues from different
molecules. Again, only experiments can verify these claims. A good experiment to
demonstrate the importance of Cys13 for the formation of these dimeric proteins, would be
to produce mutants of Cys13 to serine. Finally, as discussed above, the oligomeric states of
allergens in their natural form have far-reaching effects on IgE binding. Studying how the
oligomeric state of profilins will influence IgE binding will certainly be a worthwhile goal
to examine the basis of the allergenic potency of some profilins that are denoted as major
allergens.

Henceforth, antibodies specific to major allergens will be produced and

characterized in complex with profilins.
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TABLES
Table 2.1: Data collection, processing and refinement statistics for
Cuc m 2.0101 and Art v 4.0101.
Protein/PDB code

Art v 4.0101/6B6J

Cuc m 2.0101/6MBX

Diffraction source

APS 22-ID

APS 19-BM

Wavelength (Å)

1.000

0.979

Temperature (K)

100

100

Space group

P31

C2

a, b, c (Å)

32.7, 32.7, 81.8

102.6, 59.2, 82.9

α, β, γ (°)

90.00, 90.00, 120.00

90.00, 90.02, 90.00

Resolution range (Å)

40.00-1.90 (1.93-1.90)

40.00-2.40 (2.44-2.40)

Solvent content (%)

46

51

No. of unique reflections

7348 (374)

19535 (962)

Completeness (%)

95.5 (97.7)

99.2 (100.0)

Redundancy

2.3 (2.2)

2.5 (2.5)

〈 I/σ(I)〉

28.0 (3.5)

31.8 (2.3)

Rmeasure

0.065 (0.368)

0.042 (0.607)

Rp.i.m.

0.040 (0.233)

0.026 (0.368)

Overall B factor from Wilson plot (Å2)

34.4

63.5

CC1/2

(0.787)

(0.876)

Rcryst

0.165 (0.224)

0.231 (0.361)

Rfree

0.211 (0.291)

0.261 (0.390)

Bonds (Å)

0.013

0.010

Angles (°)

1.7

1.3

43.6

94.2

Favored (%)

97.7

96.6

Allowed (%)

2.3

3.4

0.0

0.0

R.m.s. deviations

Average B factors (Å2)
Ramachandran plot

Outliers (%)

Parameters for the highest resolution shells are in parentheses [83].
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Table 2.2: Allergens from profilin family
of proteins
Name
Aca f 2.0101
Act d 9.0101
Aeq ta 12
Ama r 2.0101
Ama v 2.01
Ama v 2.02
Amb a 8.0101
Ana c 1.0101
Api g 4.0101
Ara h 5.0101
Art v 4.0101
Art v 4.0201
Beta v 2.0101
Bet v 2.0101
Blo t 36
Bra n 8
Cap a 2.0101
Car mi 2
Che a 2.0101
Citr l 2.0101
Cit s 2.0101
Coc n 5
Cor a 2.0101
Cro s 2.0101
Cuc m 2.0101
Cyn d 12.0101
Dau c 4.0101
Fra a 4.0101
Gly m 3.0101
Hel a 2.0101
Hev b 8.0101
Hev b 8.0201
Hor v 12.0101
Jug r 7.0101
Koc s 2.0101
Lit c 1.0101
Lup a 5.0101
Mal d 4.0101
Mal d 4.0201
Mal d 4.0301
Man i 3.01
Man i 3.02
Mer a 1.0101
Mus a 1.0101
Ole e 2.0101
Ory s 12.0101
Par j 3.0101
Par j 3.0201
Pha v 5
Phl p 12.0101
Pho d 2.0101
Pla l 2.0101
Pro j 2.0101
Pru av 4.0101
Pru du 4.0101
Pru p 4.0101
Pru p 4.0201
Pyr c 4.0101
Sal k 4.0101
Sal k 4.0201
Sin a 4.0101
Sola l 1.0101
Sola t 8
Sor b 12
Tri a 12.0101
Tyr p 36.0101
Vit v 4
Zea m 12.0101

Source Common Name
Allergen Source
Needle Bush
Green Kiwi Fruit
Fruit
Tauch's Goatgrass
Redroot Pigweed
Pollen
Slender Amaranth
Pollen
Slender Amaranth
Pollen
Short Ragweed
Pollen
Pineapple
Stem
Celery
Root
Peanut
Seed
Mugwort, Wormwood
Pollen
Mugwort, Wormwood
Pollen
Sugar Beet
Pollen
Birch
Pollen
Mites
Whole body
Canola, Rapeseed
Pollen
Chilli Pepper, Bell Pepper Fruit
Florida Royal Palm
Pollen
Lambsquarters
Pollen
Watermelon
Fruit
Sweet Orange
Fruit
Coconut
Pollen
Birch, Hazelnut, Oak
Pollen, Seed
Saffron Crocus
Pollen, Stigma
Canteloupe, Muskmelon
Fruit
Bermuda Grass
Pollen
Carrot
Root
Strawberry
Fruit
Soybean
Seed
Sunflower
Pollen
Latex
Latex
Latex
Latex
Barley
Pollen
English Walnut
Seed
Burning Bush
Pollen
Lychee
Fruit
White Lupine
Seed
Apple
Fruit
Apple
Fruit
Apple
Fruit
Mango
Fruit
Mango
Fruit
Annual Mercury
Pollen
Banana
Fruit
Olive
Pollen
Rice
Pollen, Seed
Pellitory-of-the-Wall
Pollen
Pellitory-of-the-Wall
Pollen
Bean, French Bean, Kidney Bean
Seed
Timothy Grass
Pollen
Date Palm
Pollen
English Plantain
Pollen
Mesquite
Pollen
Sweet Cherry
Fruit
Almond
Seed
Peach
Fruit
Peach
Fruit
Pear
Fruit
Russian Thistle, Saltwort Pollen
Russian Thistle, Saltwort Pollen
Yellow Mustard
Seed
Tomato
Fruit
Potato
Tuber
Sorghum
Pollen
Wheat
Pollen, Seed
Storage Mite
Whole body
Grape
Fruit
Maize
Pollen

Tm Prediction
<55
<55
<55
<55
<55
<55
<55
<55
<55
<55
<55
<55
<55
<55
55-65
<55
<55
55-65
<55
<55
55-65
<55
55-65
<55
<55
<55
55-65
<55
<55
<55
<55
<55
<55
<55
<55
55-65
<55
<55
<55
<55
<55
<55
<55
<55
55-65
55-65
<55
<55
<55
55-65
55-65
55-65
<55
<55
<55
<55
55-65
55-65
<55
<55
55-65
>65
<55

Allergens highlighted in: Gray-no complete
sequence available, White- Tm <55 °C,
Orange-Tm 55-65 °C, and Red Tm >65 °C.
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FIGURES

Figure 2.1: Sequence similarities and identities between Cuc m 2.0101 and various
plant profilins. All proteins are officially registered as allergens by the World Health
Organization and International Union of Immunological Societies (WHO/IUIS) Allergen
Nomenclature Sub-committee (www. allergen.org). Proteins are colored according to
allergen source. Sequence comparison was performed using Clustal Omega [130] and
SIAS (http://imed.med.ucm.es/Tools/sias.html) [83].
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Figure 2.2: Profilins Project Flow Chart. Steps taken to
carry out the profilin project.
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Figure 2.3: SEC Elution Profile for Cuc m 2.0101. (A) Presence of profilins in the
marked peaks was confirmed using SDS-PAGE. (B) The SEC results indicate that both
monomeric and dimeric forms of Cuc m 2.0101 are generated during production of these
recombinant proteins. The elution profile for Art v 4.0101 (data not shown) is exactly the
same as figure 2.2B. Myoglobin and Vitamin B12 are used as molecular weight standards.
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Figure 2.4: DSF results for Cuc m 2.0101 and comparison to Art v 4.0101. (A) Average
melting temperatures (Tm in °C) for Cuc m 2.0101 with and without purification tag. A
gradient of salt (0.0−1.0M NaCl) and pH (4.0−9.5) buffers were used. Yellow, green, and
blue represent high, average, and low melting temperatures, respectively. (B) Melting
temperature (Tm in °C) differences between Cuc m 2.0101 and Art v 4.0101 for proteins
with and without purification tag. Yellow, green, and blue represent high, average, and low
melting temperature differences respectively. The standard deviation was less than 1°C for
all experiments [83].
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Figure 2.5: DSF Results for Phl p 12.0101 and comparison to Amb a 8.0101, Ar v
4.0101 and Bet v 2.0101. (A) Average melting temperatures (Tm in °C) for rPhl p 12.0101
with and without purification tag. Yellow and blue represent high and low melting
temperatures, respectively. (B) Melting temperature (Tm in °C) differences between rPhl
p 12.0101 and rAmb a 8.0101. (C) Melting temperature differences between rPhl p 12.0101
and rArt v 4.0101. (D) Melting temperature differences between rPhl p 12.0101 and rBet
v 2.0101. Yellow and blue represent high and low differences in the melting temperatures,
respectively. The standard deviation for the presented values was less than 1°C for all
experiments [84].
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Figure 2.6: Structure of Art v 4.0101. Sequence identity and similarity between Art v
4.0101 and Cuc m 2.0101 shown on the Art v 4.0101 structure (PDB code 6B6J). The top
images are cartoon representation with the cysteine residues shown in stick representation
while the bottom images show surface representation. In Cuc m 2 there is no cysteine that
corresponds to Cys95 of Art v 4. This amino acid is replaced by Thr residue and therefore
no internal disulfide bridge is present in Cuc m 2. Grey indicates identical residues, and
green is used to marked residues that are similar, but not identical. Regions displayed in
purple display neither identity nor similarity [83].
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Figure 2.7: Sequence conservation in all allergenic
profilins in the PDB. (A) Secondary structure elements are
marked for Zea m 12.0101 (PDB code 5FEF) and Art v
4.0101 (PDB code 6B6J), respectively. Cysteine residues
forming disulfide bridges in Amb a 8.0101 and Art v 4.0101
are marked using green boxes. (B) Conservation of profilin
sequences mapped on structure of Cuc m 2.0101 presented
in cartoon representation. Residues that are conserved in all
analyzed allergenic profilins herein (Table 2.2) are marked
in red. Residues from profilins that have their structures
determined and are completely conserved are shown in red
and salmon. It implicates that salmon corresponds to
residues that are conserved for profilins shown in this
figure, but which are not completely conserved among all
analyzed profilins. N- and C-terminal residues are marked
with corresponding letter. (C) Conservation of sequences
mapped on molecular surface of Cuc m 2.0101 [83].
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Figure 2.8: Identified epitopes and mimotope for Cuc
m 2.0101. [83] (A) Cartoon (top) and surface (bottom)
representations of Cuc m 2.0101 with mapped IgE
epitopes as determined by Lopez-Torrejon et al. [121].
N- and C-terminal residues are marked with
corresponding letters. Epitope 1, consisting of residues
66–75 and 81–93, in wheat, epitope 2 (residues 95–99
and 122–131) in brown, epitope 3 (residues 2–10) in
light teal, and epitope 4 (residues 35–45) in light pink.
(B) Mimotope determined by Tordesillas et al. and
consisting of residues 2–3, 5–6, 9–10, 111–114, 116–
117, as well as 121–122 is shown in light blue [131].
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Figure 2.9: Dimeric and monomeric profilins. (A) Dimeric structure of Hev b 8.0101.
(B) Cuc m 2.0101 (surface representations) superposed on one of the molecules forming
Hev b 8.0101 dimer. Epitope 1 is marked in wheat, epitope 2 in brown, epitope 3 in light
teal and epitope 4 in light pink. (C) Cuc m 2.0101 with modeled polyproline peptide
(shown in sphere representation). The peptide binding site is formed by residues forming
epitopes 2 and 3 identified by Lopez-Torrejon et al. [121] (D) Mimotope determined by
Tordesillas et al. [131] (light blue). Cys residues that may be responsible for formation of
a dimeric structure is marked in orange. (E) Putative Cuc m 2.0101 dimer interface based
on structure homology of Hev b 8 (PDB code 5FEG). Residues marked in blue are
completely conserved, while residues shown in purple are not conserved [83]. Figures were
generated in Pymol.
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Figure 2.10: Representative results of ELISA inhibition assay. IgE
binding to Amb a 8.0101, Art v 4.0101, Bet v 2.0101, and Phl p 12.0101
of a serum with predominant sensitization to Art v 4 was tested.
Increasing concentrations of either (A) Phl p 12.0101 or (B) Art v
4.0101 were used as inhibitors [84].
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Figure 2.11: Comparison of Amb a 8, Art v 4, Bet v 2, and
Phl p 12 sequences. All isoallergens reported by the World
Health Organization (WHO) and International Union of
Immunological Societies (IUIS) Allergen Nomenclature Subcommittee (allergen.org) are shown. (A) Sequence alignment
generated using Clustal Omega [17] and ESPript [18]. (B)
Sequence identities and similarities between the profilins as
calculated by SIAS (http://imed.med.ucm.es/Tools/sias.html)
using the default parameters [84].
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CHAPTER 3
A ROBUST METHOD FOR THE ESTIMATION AND VISUALIZATION
OF IGE CROSS-REACTIVITY LIKELIHOOD BETWEEN ALLERGENS
BELONGING TO THE SAME PROTEIN FAMILY1

3.1 INTRODUCTION TO A-RISC INDEX
As scientists not only are we interested in mitigating allergic reactions as discussed
in the previous chapters, but we are also committed to stopping them before they even
happen. In the quest to rid mankind of allergic diseases, significant amounts of time have
been invested in studying the cause of allergic diseases. Centuries of research in the human
immune system mechanisms and functions, as well as, on the development of allergic
diseases has established an irrefutable fact that immunoglobulin E, IgE, is the instigator of
most of the diverse and sometimes fatal allergic reactions associated with allergic diseases
[27]. IgE immune responses are called “immediate hypersensitivity,” and this depiction not
only denotes the extreme nature of IgE sensitivity to allergens, but also the tremendous
speed in which the immune response takes place [27].

_________________________________
1

Chruszcz M., Kapingidza A. B., Dolamore C. and Kowal K. 2018. PloS One 13 (11):
e0208276
Reprinted here with permission of publisher.
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Interactions between IgE and allergens are crucial for allergic diseases, as the
formation of an allergen-antibody complex is necessary for triggering an allergic reaction.
The IgE-mediated allergic reaction requires an allergen to cross-link antibodies bound to
the high-affinity receptors located on mast cells [8]. Therefore, in molecular allergology
there is significant effort directed to understanding interactions between allergens and
antibodies [132,133]. For example, such efforts aim to identify IgE binding epitopes and
epitope-paratope interactions [133].

Although allergen-antibody interactions may be

studied using various methods, structural biology provides one of the best insights into this
molecular phenomenon [43]. Thanks to advancements of X-ray crystallography and NMR,
we can picture epitopes as being relatively small fragments of proteins recognized by
antibodies. Structural biology also provides insight on the structures of many allergens
[43,133]. Therefore, in most cases, it is possible through homology modeling to elucidate
information on the tertiary structure of these molecules provided that the protein sequence
is available.
Because, IgE binding epitopes are conformational, they can experience substantial
cross-reactivity with proteins of high sequence identity, especially of surface residues.
Cross-reactivity occurs when antibodies raised against one allergen, cannot distinguish
between that allergen and a structurally similar protein, and thus, binds to the secondary
protein [134]. In the process to understand cross-reactivity between allergens, a minimal
approach may use only the information on sequence identity for an estimation of a crossreactivity likelihood; or combine such information with phylogenetic analysis leading to
the elucidation of evolutionary relation between allergens that are recognized by the same
antibodies. For example, it was proposed that, in most cases, cross-reactivity requires more
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than 70% sequence identity and is rare when the sequence identity falls below 50% [135].
Evidently, these simple rules appear to help in effectively predicting the observed IgE
cross-reactivity. However, the comparison of allergens, and especially the prediction of
allergenicity, can be significantly more complex than desired as there are various dedicated
computational tools that allow us to perform such analysis [136,137].
Nonetheless, here [9] we introduced a simple approach, the A-RISC Index
(Allergens’–Relative Identity, Similarity and Cross-reactivity), that uses information on
the primary structures of allergens in combination with various assumptions and
observations related to their interactions with antibodies. The A-RISC index is a single
numerical value used to predict the likelihood of IgE cross-reactivity of two allergens
belonging to the same protein family. The A-RISC index takes advantage of the fact that
some allergens’ families have many identified and characterized members which in turn
allows us to derive more precise guidelines to estimate the likelihood of cross-reactivity
between members of the same protein family. It must be stressed that we focused on crossreactivity (we assume that there was one sensitizing allergen), and we are not interested in
multi-sensitization, as the multi-sensitization refers to the generation of unrelated IgE
responses [138]. It is also assumed that in the case of allergy we face the polyclonal crossreactivity [139]. Moreover, we concentrate on cross-reactivity between allergens belonging
to the same protein family that share the same overall fold.
In our PloS One article [9], we presented cross-reactivity analysis of ten allergen
families using the A-RISC index and contrast our findings with reports on IgE crossreactivity determined using experimental approaches. However, in this manuscript only
three families, papain-like cysteine proteases, Niemann-Pick proteins type C2 (NPC2) and
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profilins will be discussed. Our approach to the analysis of allergens’ sequences not only
considers possible interactions with antibodies, but also results in a single numerical value
that describes the likelihood of cross-reactivity between two allergens originating from the
same family of proteins. Based on our analysis, we proposed the introduction of four
categories describing a risk of a cross-reactive reaction, namely: high, medium-high,
medium-low, and low. We believe that this proposed model is a better estimate of possible
cross-reactivity for pairs of allergens having low or medium levels of sequence identity.
Moreover, the proposed approach may facilitate analysis in component-resolved allergy
diagnostics and generation of avoidance guidelines for allergic individuals or help with the
design of immunotherapy.
3.2 SELECTION OF ALLERGENS
The selected allergen families had at least 13 representative proteins and overall
folds that differ significantly [9], but also include relevant allergens with various potencies
(Table 1). Protein sequences were obtained by searching Allfam [3], Allergome [140] and
Allergen Nomenclature databases [141]. Only proteins with complete sequences were
considered. Furthermore, the sequences used for analysis correspond to the mature version
of proteins (signal- and pro-peptides were omitted). This study included allergens that are
registered by the World Health Organization and International Union of Immunological
Societies (WHO/IUIS) Allergen Nomenclature Sub-committee (www.allergen.org) as well
as allergens that are listed by Allergome and/or Allfam and not officially registered.
In case of officially registered allergens, the full nomenclature name which includes
four digits after a period in the numerical part of an allergen symbol was used [141]. Many
of the allergens selected have several isoallergens reported. For the isoallergens that have
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the same digit in the second place, only one representative sequence was chosen and, most
often, it was the isoallergen with full nomenclature name ending with a 1. This approach
is related to the fact that currently the third and fourth digits of the nomenclature name are
determining variants of an isoallergen, with the variant usually having more than 90%
sequence identity [141]. However, in some cases when a full sequence for such a protein
was not available, isoallergens with names having 2 in the fourth place after the period
were chosen. The selected sequence of allergens belonging to each family were stored in
Fasta format.
3.3 ANALYSIS OF SEQUENCES
Multiple sequence alignment of proteins belonging to a single family were
performed with clustal Omega [130]. Sequence similarities and identities were calculated
with SIAS (http:// imed.med.ucm.es/Tools/sias.html) using the default parameters. The
SIAS webpage divides amino acids into the following similarity groups: aromatic (F, Y
and W), aliphatic (I, L and V), positively charged (H, K and R), negatively charged (D and
E), small with hydroxyl group (S and T) and neutral polar (N and Q). The five remaining
amino acids (A, C, G, M and P) are not included to any similarity groups. Sequence
similarities and identities calculated with SIAS were stored and used for the generation of
various plots as well as for A-RISC calculations (Allergens’–Relative Identity, Similarity
and Cross-reactivity) indexes. In the manuscript [9], an A-RISC index for a particular pair
of proteins is defined as an average of the proteins’ sequence similarity (S), as calculated
by SIAS server, and identity (1). The index we propose is a single numeric value that
provides information on relative homology between allergens from a particular protein
family and a selected member of this family. In the case of allergens, a physical meaning
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of the A-RISC index can be explained by considering interactions of these proteins with
antibodies [9]. For example, most epitope and paratope recognition is mediated by
hydrogen bonds, hydrophobic interactions and shape complementarity. The presence of the
same or similar amino acids in the corresponding regions of two proteins may lead to a
situation whereby the same antibody will fail to discriminate between the proteins, as the
paratope will be able to form interactions with the same or similar epitopes that are present
in both proteins (allergens).
In this model, we made several assumptions that allow for the simplification of the
comparison of two allergens as well as allergen-antibody interactions. For example, we use
only information on allergen sequences (primary structure) and ignore secondary and
quaternary structures. The only assumption on the tertiary structurers is related to the fact
that proteins from the same family generally adopt the same overall fold. Furthermore, we
presume that when two protein sequences are compared, we can divide the compared
amino acids into three groups: identical, similar, and not similar. We define similar as:
“similar” = “identical” + “similar, but not identical”. Additionally, we assume that in the
case of two allergens belonging to the same protein family, only identical and similar amino
acids are responsible for cross-reactivity. We also make an assumption that in the cases of
non-identical, but similar amino acids, only in 50% of cases will we observe participation
of these residues in binding of a cross-reactive antibody. The previous two assumptions
allow us to write the following equation that describes a fraction of all amino acids which
may be responsible for interaction with a cross-reactive antibody:

𝐼+

𝑆−𝐼
2

=
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𝐼+𝑆
2

(1)

and provide the formula for calculation of the A-RISC index. In the equation I stands for
Identical residues and S, similar but not identical residues. An example of the proposed
here comparison of two allergens is illustrated in Figure 3.1. One should note that the
difference between A-RISC and sequence identity (expressed as fraction) values will be
small for pairs having high sequence identity. However, A-RISC values will be
significantly higher than corresponding identities for pairs of proteins with low or medium
sequence identities. Using the above mentioned formula, the likelihood of IgE crossreactivity between the three protein families, papain-like cysteine proteases, Niemann-Pick
proteins type C2 (NPC2) and profilins, discussed in this manuscript were calculated and
the results compared to experimental findings annotated in literature.
3.4 A-RISC INDEX FOR PAPAIN-LIKE CYSTEINE PROTEASES
This is the family where Group 1 HDM allergens (Der p 1 and Der f 1), discussed
earlier in chapter 1, belong. In their mature form, the papain-like cysteine proteases (clan
CA and family C1) [142] are monomeric proteins composed of approximately 220 amino
acids [30]. The active site is located between two globular domains (Figure 3.1B), and the
proteolytic activity of these enzymes was reported to contribute to their allergenicity [22].
There are several human homologs of these proteins, like cathepsins, that have a similar
overall architecture, but have a relatively low sequence identity exemplified by human
cathepsin K, which is most similar to Der f 1, as the enzymes share 36% of identical
residues [73]. This family of allergens contains proteins originating from both animals and
plants. Eleven of these proteins originate from mites (Group 1 mite allergens), one from a
tick (Boo m 1) and three from plants (Act d 1, Amb a 11 and Ana c 2). The allergens from
this family differ significantly in sequence (Table 3.1).
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The most frequently recognized allergens from this protein family are excreted by
the HDM, Der p 1 and Der f 1 [143]. Analysis of the relative sequence identities and
similarities, as well as the plots with A-RISC index (Figure 3.2A) clearly show that Der p
1, Der f 1, and Eur m 1 are similar, and thus, there is a high risk of IgE cross-reactivity
between these proteins. Conversely, there is a significantly lower chance of cross-reactivity
between the three HDMs allergens and other members of the allergen family [9]. The only
exemption is Pso o 1 that has ~64% sequence identity and ~70% similarity to Der p 1, Der
f 1 and Eur m 1, and therefore has a significant chance to be involved in a cross-reactive
reaction with the aforementioned allergens [144]. In addition, our analysis shows that in
case of individuals that were sensitized with Blo t 1.0101 there is a relatively low risk of a
cross-reactive reaction with other cysteine proteases presented therein (Figure 3.2B).
Interestingly, in the case of Blo t 1, the difference in sequence between isoallergens
(Blo t 1.0101 and Blo t 1.0201) is quite significant. This also clearly highlights differences
between proteins originating from HDMs and storage mites and is consistent with limited
cross-reactivity between these allergens observed among mite allergic individuals
[145,146]. Figure 3.2B also suggests that a cross-reactive reaction between Blo t 1 is more
likely to be observed with Sui m 1 (Suidasia medanensis), Tyr p 1 (Tyrophagus
putrescentiae) and Aca s 1 (Acarus siro) than with Der p 1 or Der f 1. This observation is
consistent with results of cross-reactivity between allergens from S. medanensis and B.
tropicalis reported for an urban area of Cartagena (Spain) [147]. In this report, according
to RAST and immunoblot inhibition experiments, a significant inhibition of IgE binding to
Blo t 1 (corresponding to 25 kDa of B. tropicalis protein) could be achieved with S.
medanensis extract.
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The analysis of A-RISC indexes for the whole family of allergens (Figure 3.3)
shows a low risk of cross-reactivity between allergens originating from mites and plants.
The highest risk of cross-reactivity is related to proteins originating from HDMs, whilst
that of proteins from storage mites is lower, as they are less similar between themselves.
Data presented in Figure 3.3 also indicate a medium-high risk of cross-reactivity between
proteins from Aleuroglyphus ovatus (Ale o 1, brown legged grain mite) and Boophilus
microplus (Boo m 1, southern cattle tick).
3.5 A-RISC INDEX FOR NPC2 FAMILY
NPC2 (NPC intracellular cholesterol transporter 2, Niemann-Pick proteins type C2)
is the family where Group 2 HDM allergens (Der p 2 and Der f 2), discussed in chapter 1,
belong to. Proteins belonging to the NPC2 family are composed of approximately 130
amino acids that form a single β-sandwich domain (immunoglobulin-like tertiary structure)
[44,148]. These proteins do not have an enzymatic activity, but they are able to
accommodate various ligands [149]. Human NPC intracellular cholesterol transporter 2
shares 25% of identical residues with Der p 2 and was shown to mimic human MD-2, a
liposaccharide binding component of Toll-like receptor 4 signaling complex. This
molecular mimicry is most likely responsible for Der p 2 allergenicity [25].
NPC2 proteins are present in arthropods and vertebrates [150], however, allergens
from this family originate primarily from mites (Group 2 mite allergens) with only two
allergens that have a different source (Can f 7 – dog and Ixo r 2 – castor bean tick).
Currently, neither food nor plant allergens are reported as being members of this family.
Analysis of relative sequence homology shows a situation similar to the case of the cysteine
proteases. Namely, Der p 2, Der f 2, and Eur m 2 are similar with sequence identities over
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80% and sequence similarities over 90%. Other allergens have less than 50% sequence
identity when compared to Der p 2.0101 (Figure 3.4A). At the same time, Blo t 2 (Figure
3.4B) is quite distinct from other members of the family with Sui m 2 and Der f 35 having
the highest sequence identity of 56% and 52% respectively. Analysis of the sequences of
proteins originating from HDMs and storage mites is consistent with observed clinical
cross-reactivity. It was shown that there is limited cross-reactivity between Group 2
allergens from D. pteronyssinus and B. tropicalis, Glyciphagus domesticus or
Lepidoglyphus desctructor; while there is cross-reactivity between Lep d 2, Gly d 2 and
Tyr p 2 [151-153]. These observations are in agreement with our results as depicted on
Figures 3.4 and 3.5. On the other hand, it was shown that cross-reactivity between Der p 2
and Tyr p 2 may be quite significant [154], despite the sequence identity being below 40%.
Furthermore, our analysis reveals that the highest potential risk of cross-reactivity between
Group 2 mite allergens originating from HDMs and Blo t 2.0101 is associated with Der f
35, and not Der f 2, Der p 2 or Der f 22 (Figure 3.6).
There are three allergens belonging to the NPC2 family and originating from D.
farinae: Der f 2, Der f 22 (33%/40% of sequence identity/similarity to Der f 2) and Der f
35 (41%/57% of sequence identity/similarity to Der f 2). Both Der f 2 and Der f 35 are
considered to be major allergens, while Der f 22 is a minor allergen [155]. Using these
allergens as examples it can be shown that proteins could have quite distinct sequences
despite belonging to the same family and originating from a single organism (Figures 3.4A
and 3.5). Conversely, the presence of several allergens in one source may cause a
complicated pattern of cross-reactive reactions. For example, Der f 35 was shown to be not
only cross-reactive with Der f 2, but also with Pso o 2 [155].
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Our results also demonstrate that Can f 7 most likely will not be involved in crossreactive reactions in individuals that are sensitized with Group 2 mite allergens, because
this dog allergen shares only 22-31% identical and 37-42% of similar residues with the
corresponding mite allergens. A similar situation is observed for Ixo r 2 that shares only
28-34% of identical and 41-50% of similar residues with the corresponding mite allergens.
3.6 A-RISC INDEX FOR PROFILINS
Profilins, the family where Cuc m 2, Art v 4 and Phl p 12 discussed in chapter 2
belong, were identified as allergens almost four decades ago [116,156]. They are small
(~130 amino acids), multifunctional proteins present in either a monomeric or dimeric form
[116] with one of their most important features being their ability to interact with many
proteins by binding to the poly-proline fragments [156]. Profilins are highly conserved in
terms of their sequence (Table 3.1, Figure 3.7) and structure as they are considered to be
the only true panallergens [10]. Profilins originating from plants are especially similar as
they are responsible for various cross-reactive reactions [157]. This is consistent with our
results as A-RISC index values for plant profilins are in 0.73-0.99 range. The two profilins
originating from storage mites (Blo t 36 and Tyr p 36) are similar to each other, but they
significantly differ in sequence when compared to plant profilins (Figures 3.7 and 3.8).
Allergens from this family are structurally similar to human profilins, however sequence
identity with human homologs is smaller than 25% [88,158].
The most common reactions involving allergens from the profilin family are
associated with Oral Allergy Syndrome (OAS; also known as Pollen-Food Syndrome)
which is considered a class II food allergy. In this syndrome, an allergen from pollen is the
sensitizer while the related food allergen is the elicitor of symptoms [159]. The origin of
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OAS may be explained using Figure 3.8 as an illustration. In this case, it is assumed that
birch pollen profilin (Bet v 2.0101) is responsible for the sensitization, and due to the high
homology with food profilins such as apple (Mal d 4.0301), pear (Pyr c 4.0101), carrot
(Dau c 4.0101), and celery (Api g 4.0101), cross-reactive reactions are observed. This is
also reflected by clinical sensitization patterns. In Northern Europe, where sensitization to
birch allergen is common, Bet v 1 and Bet v 2 are responsible for birch-celery syndrome.
A similar situation is observed in the case of OAS involving birch and apple, where
other allergen families like PR-10 and profilin allergens are involved in cross-reactive
reactions [160]. In the areas where there is no exposure to birch allergens, profilins from
weeds (Amb a 8 and Art v 4), grass (Phl p 12), olive (Ole e 2) or date palm (Pho d 2) may
replace Bet v 2 as potential sensitizing allergens [161,162]. This results in various pollenfood syndromes including mugwort-celery, mugwort-peach, ragweed-melon-banana,
grass-fruit and plant-fruit. [91,121,122,163]. In summary, the comparison of profilins
sequences not only shows why cross-reactivity between these allergens is so wide-spread,
but also explains the high-risk of such events. It also shows why using one profilin may be
sufficient in diagnosing sensitization to all other plant profilins [5,112]
3.7 DISCUSSION
Sequence Identity and A-RISC Index
The analysis of the ten allergen families presented herein [9] showed that even
simple models that are based on protein sequences may be very helpful in understanding
molecular bases of cross-reactivity. Moreover, such analysis can provide an explanation
for clinically observed cross-reactivity patterns. In our opinion, analysis of sequence
identities only is a minimal approach that may underestimate the risk of cross-reactivity.
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Introduced here, the A-RISC index is a step forward towards a better estimation of
the likelihood of cross-reactivity, and when combined with structural information,
illustration of the homology between pairs of allergens can be better elucidated (Figures
3.1 and 3.9). Moreover, it clearly shows why similar, but not identical residues can play a
role in cross-reactivity, especially for proteins that have a relatively low sequence identity
(Figure 3.9). For example, only consideration of identical and similar residues combination
explains why a cross-reactive reaction between Bet v 1 and Act d 11 may be observed
[164]. In this case, we are able to explain the formation of continuous patches on the surface
of Act d 11 that may correspond to epitopes responsible for binding IgE antibodies
developed against Bet v 1 [164]. Such surface patches corresponding to epitopes usually
have an area of ~800 Å2 [133].
Despite various limitations, the model that we propose robustly predicts crossreactivity patterns that were extensively elucidated experimentally. Based on our analyses,
we propose to amend the original rules for allergen cross-reactivity proposed by Aalberse
[165] and introduce the four new following categories of cross-reactivity likelihood: high
(A-RISC values  0.75), medium-high (0.75 > A-RISC  0.50), medium-low (0.50 > ARISC  0.25) and low (A-RISC values < 0.25).
Allergen families that contain at least several members may be ranked according to
their propensity for cross-reactive reactions. Such a ranking may be created by calculating
an average A-RISC index for the whole family. For allergen families analyzed by us [9],
but not all discussed in this manuscript (Figure 3.10), the propensity for cross-reactivity is
as follows (average A-RISC indexes and sequence identities are reported in parenthesis):
profilins (0.80, 76%), (0.56, 51%), NPC2 family (0.48, 41%) and cysteine proteases (0.42,
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37%). It must be noted that this ranking corresponds to currently reported allergens, and
patterns of cross-reactivity will strongly depend on allergen exposure.
A-RISC index – Limitations of the Current Approach
The A-RISC model, although a robust method for predicting IgE cross-reactivity
between two allergens belonging to the same protein family, has various limitations. For
example, this method considers sequences, whilst possible posttranslational modifications
of the amino acids are ignored. Post-translational modifications resulting in the presence
of hydroxyprolines, carbohydrates and other less common chemical moieties sometimes
have a significant impact on the allergenic properties of proteins [10,166,167]. We also
omit the fact that some of the ligands that are carried by allergens may impact the
allergenicity of proteins. Moreover, even when considering only the protein sequence, we
can improve the current approach by trying to map the sequence conservation on an
allergen model and estimate whether the conserved residues that form patches or stretches
are large enough to become epitopes (both continuous and discontinuous). As we do this,
we might also need to consider that the conserved residues tend to cluster in parts of a
protein important for the function and/or structure of the molecule. In addition, we did not
incorporate any knowledge on IgE epitopes that was previously determined. Similarly, for
allergen families like cysteine proteases or profilins, which have human homologs, we did
not use these sequences of human proteins to adjust our model [168]. To improve the
current A-RISC model these factors must be assimilated in the predictions.
Applications of the A-RISC Index
Currently, many diagnostic tools that can be used to detect IgE binding directed to
individual allergenic proteins are available. Tests including multiplex platforms provide a
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great body of information concerning IgE binding to individual allergens. Understanding
the cross-reactivity of individual allergenic proteins may help in explaining the results of
allergy testing [169,170]. Therefore, we are convinced that the A-RISC index can be used
to interpret results originating from component resolved allergy diagnostics. Considering
the problem of allergen cross-reactivity that is often encountered in allergy diagnosis,
analysis of IgE reactivity to individual allergens may allow for better selection of true
sensitizers in patients allergic to multiple allergens.
In addition, it may help to design appropriate composition of vaccines and
immunotherapeutics used for allergy immunotherapy. Several reports provide evidence of
how individual allergens present in vaccines may induce a protective immune response to
cross-reactive allergens [171,172]. Moreover, the idea of analyzing allergens in the context
of protein families, like in the calculation of A-RISC indexes, should provide better
avoidance guidelines, as they may include not only information on molecules that are
suspected to be the primary sensitizers, but also provide a list of allergens (and their
sources) that may be involved in various cross-reactive reactions. Furthermore, the
sequence derived guidelines, for example based on A-RISC indexes, are able to provide a
general categorization of the likelihood of cross-reactivity.
The analysis of allergen families also shows that due to their internal diversity, or
lack thereof, proteins will be related to each other with completely different patterns of
possible cross-reactivities. For example, allergenic profilins and serum albumins will be
most likely associated with high likelihood of cross-reactivity, while it may be not true for
other allergen families. It is also important to highlight that even in one allergen family,
one can delineate several subgroups of proteins that are more likely to be responsible for
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cross-reactivity. The categorization of the relative patterns of sequence identities and
similarities may further facilitate prediction of the likelihood of cross-reactivity including
allergenic proteins not yet characterized.
In summary, the A-RISC index identifies true “allergen culprits” for patients with
multiple allergies. Identifying true sensitizers will help design vaccines that are effective
to all other cross-reactive allergens.

Our ultimate goal is to design an algorithm

incorporating A-RISC indexes as part of a software that will help physicians to “navigate
through the jungle of allergens” in order to provide accurate predictions for IgE crossreactivity thereby generating reliable avoidance guidelines for patients, and a good starting
point for allergy diagnosis for allergists.
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TABLES
Table 3.1 Summary on sequence identity and similarities of papain-like cysteine
proteases, NPC2 and profilin allergen families.
Allergen
family
ID

# of
allergens

identity

similarity

identity

similarity

Papain-like
cysteine
proteases
(Group 1
mite
allergens)

AF030

15

37%

50%

21-85%

30-88%

NCP2 family
(Group 2
mite
allergens)

AF111

17

41%

58%

22-90%

34-95%

Profilins

AF051

64

76%

84%

32-99%

43-99%

Protein
family

Average sequence

Range of sequence

Amino acid identity and similarity varies widely within each group [9].
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FIGURES

Figure 3.1: Comparison of Der p 1.0101 and
Blot 1.0101. (A) Sequence alignment of Der p
1.0101 and Blo t 1.0101 made with Clustal Omega.
Similar residues are marked with bold font type.
Identical residues-red, blue-the difference between
similar and identical residues. (B) Similar amino
acids (blue) marked on the structure of Der p 1.
The structure is shown in ribbon (top) and spacefilling representation (bottom). (C) Identical
amino acids (red) mapped on the structure of Der
p 1. Residues marked in light blue correspond to
the difference between similar and identical
residues. We assume only 50% of these residues
are involved in IgE cross-reactivity [9].
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Figure 3.2: Relative homology and A-RISC indexes of allergens from the papain-like
cysteine protease family. Comparison of other family members to Der p 1.0101 (A) and
Blo t 1.0101. (B) Allergens originating from plants are shown in green. Red, gray and dark
green dashed lines indicate 75%, 50% and 25% sequence identity and similarity
respectively, or 0.75, 0.50 and 0.25 A-RISC values [9].
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Figure 3.3: A-RISC index values for allergen pairs from the papain-like cysteine
protease family. Red color indicates a high risk of cross-reactivity, a dark green color
indicates a low risk of cross-reactivity, and intermediate colors correspond to a medium
risk of cross-reactivity [9].
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Figure 3.4: Relative homology and A-RISC indexes of allergens from the NPC2
family. Comparison of family members to Der p 2.0101 (A) and Blo t 2.0101. (B) Red,
gray, and dark green dashed lines indicate respectively 75%, 50% and 25% sequence
identity and similarity, or 0.75, 0.50 and 0.25 A-RISC values [9].
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Figure 3.5: Relative homology and A-RISC indexes of allergens from the NPC2
family. Comparison of family members to Der f 35.0101. (A) and Lep d 2.0101 (B) Red,
gray, and dark green dashed lines indicate respectively 75%, 50% and 25% sequence
identity and similarity, or 0.75, 0.50 and 0.25 A-RISC values [9].
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Figure 3.6: A-RISC index values for allergen pairs from the NPC2 family. Red color
indicates a high risk of cross-reactivity, a dark green color indicates a low risk of crossreactivity, and intermediate colors correspond to a medium risk of cross-reactivity [9].
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Figure 3.7: A-RISC index values for allergen pairs from profilin family of proteins.
Red color indicates a high risk of cross-reactivity, a dark green color indicates a low risk
of cross-reactivity, and intermediate colors correspond to a medium risk of cross-reactivity
[9].
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Figure 3.8: Relative homology of allergens from profilin family. Comparison of family
members to Bet v 2.0101. Only selected members of the family are labeled. Red and gray
dashed lines indicate respectively 75% and 50% sequence identity and similarity, or 0.75,
and 0.50 A-RISC values [9].
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Figure 3.9: Comparison of Bet v 1.0101 with Act d 11.0101, Ara h 8.0101 and Cor a
1.0101. Identical amino acids (red) mapped on the structure of Bet v 1. Residues marked
in light blue correspond to the difference between similar and identical residues [9].

124

Figure 3.10: A-RISC indexes for various allergen families. Gray bars correspond to
observed A-RISC ranges. The black horizontal lines indicate an average A-RISC index for
a family [9].
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CHAPTER 4
SUMMARY AND CONCLUSIONS
There are more than a thousand allergens known to man emanating from different
sources and these allergens are associated with various allergic diseases. This research in
the Chruszcz laboratory, focused on aeroallergens from dust mites and pollens, as well as,
food allergens. Among the most potent allergens in allergic diseases are dust mite allergens.
Dust mites are arthropods that live in warm areas of high humidity and feed on human skin
flakes. In households, dust mites are found almost everywhere including beds, carpets, and
other furniture. Of the more than 35 groups of house dust mite (HDM) allergens registered,
Group 1 and 2 HDM allergens elicit IgE response in more than 85% of sensitized
individuals. These allergens affect 10-30% of the world’s population. Prolonged inhalation
of low doses of HDM allergens by genetically predisposed individuals leads to the allergic
diseases like asthma, rhinitis and atopic dermatitis.
Among 85% of sensitized individuals, IgE-mediated immune response is elicited
from two major dust mite species, Dermatophagoides farinae and Dermatophagoides
pteronyssinus, and Der p 2 originates from the latter. We characterized the crystal structure
of Der p 2 in complex with monoclonal antibody 7A1. We hypothesized that
characterization of molecular and antigenic properties of allergens is necessary for the
development of better allergy diagnostics and therapeutics. To test this hypothesis, we
studied Group 1 and Group 2 allergens and their interactions with antibodies. The ultimate
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goal of the project was to produce hypo-allergens (allergen-mutants) that have considerably
reduced binding to IgE antibodies which could be used for immunotherapy.
The research was carried out in three steps: (1) Expression, purification and
characterization of recombinant isoallergens (variants of the same allergen differing in one
to three amino acid residues) and IgE/IgG antibody fragments (selected from
combinational libraries designed from HDM allergic patients), (2) Identification of
IgE/IgG epitopes on Group 2 allergens by generating antibody-antigen complexes, and (3)
Design and production of modified Group 2 allergens with reduced IgE binding affinity.
Since most IgE epitopes are conformational, X-ray crystallography provided detailed
three-dimensional structural features of the IgE antibodies in complex with allergens,
unveiling the important residues responsible for antibody-antigen interactions. Hence, after
the identification of these “hot-spots,” using site-directed mutagenesis, two double mutants
on the 7A1 epitope were generated.
IgE binding affinities between the wild type natural and/or recombinant allergen
and the mutants were compared using ELISA. As expected, the mutants had reduced
binding to human IgE of 10-100-fold. These allergen mutants, hypoallergens, are good
candidates in the development of HDM vaccines and immunotherapy. Two manuscripts
originate from this project: “A Human IgE Antibody Binding Site on Der p 2 for the Design
of a Recombinant Allergen for Immunotherapy” [26] published in Journal of Immunology
and the second one is in preparation. Since most of the antibodies used in this research
were IgG murine-derived monoclonal antibodies known to have overlapping epitopes with
IgE, the next steps to this research aims to study allergen-antibody interactions in Group 2
HDM allergy using human derived IgE monoclonal antibodies.
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Another class of allergens we studied in this research are profilins. Profilins are
small, 12-15 kDa, ubiquitous proteins that bind poly-L-proline (PLP) fragments, which
allows interaction with actin. Profilins share high sequence identity and similarity, as well
as, extremely conserved three-dimensional structures even across distant species. This
renders them as panallergens—minor allergens widespread in pollens and foods, and
responsible for immunoglobulin E cross-reactivity. Cross-reactivity occurs when the
antibodies raised against one allergen, cannot distinguish between that allergen and a
structurally similar protein, and thus, binds to the secondary protein. This cross-reactivity,
as well as others, leads to syndromes such as pollen-food syndrome. Various fruits,
vegetables and nuts share similar proteins with pollen. When IgE antibodies specific to a
particular pollen cross react with a type of food ingested by an individual, it triggers an
inflammatory reaction that will lead to an allergic reaction— characterized by symptoms
in the skin, gastro-intestinal tract, oral itching and labial edema, or respiratory system.
Although profilins are mainly regarded as minor allergens, they are important
players in IgE cross-reactivity leading to various allergic diseases including pollen-food
syndrome. In this research, the structural, molecular, and thermal stability characteristics,
as well as, possible IgE cross-reactivity between profilins were investigated. Among other
profilins characterized, Cuc m 2, a profilin from Cucumis melo (muskmelon), Art v 4 from
Artemisia Vulgaris (mugwort) and Phl p 12, a profilin from Phleum pratense (Timothy
grass), were recently studied. While most profilins are minor allergens, Cuc m 2 is a major
allergen since it can elicit IgE production in 80% of sensitized individuals. In addition, it
has high sequence and structure similarity to other major allergens like Art v 4 and Hev b
8 (latex), as well as a minor allergen, Phl p 12 which leads to IgE cross-reactivity.
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Comparison of profilins molecular, structural and antigenic properties provides new
insights into the allergenicity of this family of proteins, expedite allergy diagnostics and
facilitate the development of hypoallergenic molecules that can be exploited in
immunotherapy. Results generated in this part of the project were published in two
manuscripts: “Comparative structural and thermal stability studies of Cuc m 2.0101, Art v
4.0101 and other allergenic profilins” in Molecular Immunology [83] and “Production and
Use of Recombinant Profilins Amb a 8, Art v 4, Bet v 2, and Phl p 12 for Allergenic
Sensitization Studies” in Molecules [84]. The future directions to the profilin family project
is to study how the oligomeric state of the allergen influence the allergenicity of profilins
and how these oligomeric states alter or influence IgE binding.
As scientists not only are we interested in mitigating allergic reactions, but also in
stopping them before they even happen. In 2018, we proposed a new way of predicting IgE
cross-reactivity, the A-RISC index (Allergens’–Relative Identity, Similarity and Crossreactivity). In our PLOS One article, “A robust method for the estimation and visualization
of IgE cross-reactivity likelihood between allergens belonging to the same protein family,”
[9] four categories (high, medium-high, medium-low and low) predicting the likelihood of
IgE cross-reactivity between proteins belonging to the same family were introduced.
The A-RISC index identifies true “allergen culprits” for patients with multiple
allergies. Identifying true sensitizers will help design vaccines that are effective to all other
cross-reactive allergens. Our main goal is to design an algorithm incorporating A-RISC
indexes as part of a software that will help physicians to “navigate through the jungle of
allergens” to provide accurate predictions for IgE cross-reactivity thereby generating
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reliable avoidance guidelines for patients, and a good starting point for allergy diagnosis
for allergists.
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